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During	 evolution	 higher	 vertebrates	 were	 developing	 a	 hierarchically	 branched	 vascular	
system	 allowing	 efficient	 distribution	 of	 oxygen-	 and	 nutrient-rich	 blood	 towards	
metabolically	active	tissues	as	well	as	removal	of	cellular	waste	products.	Organ	blood	flow	
needs	 to	 carefully	 match	 tissue	 metabolism,	 as	 compromised	 blood	 flow	 in	 ischemic	
cardiovascular	 diseases,	 for	 example	 induced	 by	 atherosclerotic	 lesions	 and	 occlusion	 of	
main	 feed	 arteries,	 results	 in	 organ	 damage.	 Conversely,	 improving	 blood	 flow	 towards	
infarct	regions	either	by	promoting	growth	of	new	vessels	(angiogenesis),	or	by	stimulating	
native	arterial	collateral	bypasses	is	considered	therapeutically	relevant.		
Although	 the	 cytokine	 vascular	 endothelial	 growth	 factor	 (VEGF)	 constitutes	 in	 theory	 an	
ideal	 candidate	 for	 therapeutic	 approaches	 as	 it	 promotes	 arterial	 identity,	 vascular	
branching	 and	 remodelling,	 experimental	 and	 clinical	 trials	 with	 VEGF	 have	 thus	 far	 not	
yielded	the	expected	results.	As	vessels	 react	very	sensitive	 to	changes	 in	VEGF	 levels,	 the	
major	obstacles	 in	efficient	promotion	of	 arteriolar	outward	 remodelling	are	VEGF	dosage	
and	 location.	 An	 endogenous	 scavenger	 of	 VEGF	 and	 thus	 a	 regulator	 of	 VEGF	 receptor	
(VEGFR)-2	 (Kdrl)	 signalling	 is	 VEGFR-1	 (Flt1).	 Thus,	 we	 reasoned	 that	 balancing	 Flt1	 levels	
might	be	useful	in	tuning	local	VEGF	levels	in	the	context	of	promoting	arteriolar	growth.	
Using	 genetic	 approaches	 in	 the	 zebrafish	model	we	 demonstrated	 in	 this	 study	 that	 Flt1	
protein	 was	 predominantly	 expressed	 at	 or	 in	 close	 proximity	 of	 the	 endothelial	 cell	
membrane	 of	 arterioles.	 Loss	 of	 flt1	 stimulated	 outward	 remodelling	 of	 arterioles,	
presumably	 due	 to	 increased	 Vegfaa	 bioavailability.	 While	 vegfaa	 gain-of-function	 (GOF)	





arterioles	where	 it	 binds	 Vegfaa.	 By	 increasing	 Plgf	 levels	 Vegfaa	 is	 competed	 away	 from	
arteriolar	Flt1,	 resulting	 in	 local	 release	of	a	non-toxic,	 therapeutically	beneficial	dosage	of	
Vegfaa	 in	 close	 proximity	 to	 arteriolar	 Kdrl.	 Arteriolar	 Flt1	 may	 thus	 act	 as	 important	
regulator	of	arteriolar	diameter	in	response	to	Vegf	ligands,	and	manipulation	of	the	ligand-





Im	 Laufe	 der	 Evolution	 haben	 höhere	 Vertebraten	 ein	 hierarchisch	 angeordnetes	
Blutgefäßsystem	entwickelt,	das	die	effiziente	Versorgung	von	metabolisch	aktivem	Gewebe	
mit	 sauerstoff-	 und	 nährstoffreichem	 Blut	 sowie	 den	 Abtransport	 von	 zellulären	
Abfallprodukten	 ermöglicht.	 Die	 Abstimmung	 des	 Blutfluss	 in	 den	 Organen	 auf	 deren	
Metabolismus	 ist	 wichtig,	 da	 Beeinträchtigungen	 im	 Blutfluss	 in	 ischämischen	 Herz-
Kreislauferkrankungen,	 hervorgerufen	 z.B.	 durch	 atherosklerotische	 Läsionen	 und	
Arterienverstopfung,	 Organschädigungen	 hervorrufen.	 Umgekehrt	 wird	 eine	 Verbesserung	
des	Blutflusses	in	Richtung	einer	Infarktregion	entweder	durch	Wachstumsförderung	neuer	
Gefäße	 (Angiogenese)	oder	durch	die	 Stimulation	nativer,	 arterieller	Kollateral-Bypässe	als	
therapeutisch	relevant	angesehen.	
Obwohl	 das	 Cytokin	 vascular	 endothelial	 growth	 factor	 (VEGF)	 theoretisch	 einen	 idealen	
Kandidaten	 für	 therapeutische	 Ansätze	 darstellt,	 da	 es	 arterielle	 Identität	 sowie	
Gefäßverzweigung	und	–remodellierung	fördert,	haben	experimentelle	und	klinische	Studien	
mit	 VEGF	 bisher	 nicht	 die	 erhofften	 Ergebnisse	 erzielt.	 Da	 Gefäße	 sehr	 sensibel	 auf	
Änderungen	von	VEGF-Mengen	reagieren,	stellen	die	Dosierung	und	Lokalisierung	von	Vegf	
die	größten	Hürden	bei	der	effizienten	Stimulierung	struktureller	Arteriolenerweiterung	dar.	
Ein	 endogener	 „Fänger“	 von	 VEGF	 und	 somit	 ein	 Regulator	 der	 VEGF-Rezeptor	 (VEGFR)-2	
(Kdrl)-Signalgebung	 ist	 VEGFR-1	 (Flt1).	 Daraus	 haben	 wir	 geschlussfolgert,	 dass	 das	
Ausbalancieren	von	Flt-Mengen	zur	lokalen	Justierung	von	VEGF-Pegeln	im	Zusammenhang	
mit	SAE	nützlich	sein	kann.	
Im	 Zebrafischmodell	 konnten	wir	mittels	 genetischer	 Ansätze	 Flt1-Protein	 direkt	 auf	 oder	
zumindest	 sehr	nah	an	Endothelzellmembranen	 in	Arteriolen	nachweisen.	Der	Verlust	 von	
flt1	 stimulierte	 struktureller	 Arteriolenerweiterung,	 wahrscheinlich	 durch	 erhöhte	
Bioverfügbarkeit	 von	 Vegfaa.	 Während	 zwei	 unterschiedliche	 vegfaa	 Funktionsgewinn-
Studien	 zu	 völlig	 dysfunktionalen	 Arteriolen	 auf	 Grund	 schädlicher	 Vegfaa-Pegel	 führten,	
konnte	 eine	 Zunahme	 des	 Flt1-spezifischen	 Liganden	 placental	 growth	 factor	 (plgf)	 das	
durch	 Flt1	 gebundene	 Vegfaa	 durch	 kompetitives	 Binden	 befreien.	 Dies	 führte	 zu	 Akt-






arteriellem	 Flt1	 vertrieben,	 was	 zu	 einer	 lokalen,	 nicht-toxischen	 und	 therapeutisch	
vorteilhaften	Freisetzung	von	Vegfaa	nah	an	arteriellem	Kdrl	führt.	Arterielles	Flt1	ist	somit	
ein	 wichtiger	 Regulator	 des	 Arteriendurchmessers	 in	 Bezug	 auf	 Flt1-Liganden,	 und	 die	





































lead	 to	 embryonic	 lethality	 unequivocally	 emphasizes	 the	 importance	 of	 the	 vasculature	
during	 development.	 Also	 in	 the	 adult,	 malfunctions	 of	 the	 cardiovascular	 system	 are	
devastating,	giving	rise	to	some	of	the	most	pervasive	lethal	conditions	in	Western	countries	






factors	 are	 needed	 to	 keep	 it	 in	 a	 fully	 functional	 condition	 are	 crucial	 to	 tackle	
cardiovascular	pathologies	as	well	as	many	neurological	disorders	in	the	clinic.	
By	 looking	 in	detail	 at	 the	 functional	 anatomy,	 cellular	mechanisms	and	molecular	players	
that	 are	 essential	 in	 vessel	 growth,	 developmental	 biology	 can	 give	 answers	 to	 many	
questions	that	are	currently	unsolved.	Such	findings	may	translate	into	clinical	applications,	





Based	on	 functional	anatomical	 terms,	 the	circulatory	system	 in	higher	vertebrates	can	be	
divided	 in	 two	 different	 system:	 the	 blood	 vascular	 system,	 which	 is	 a	 closed	 tubular	
network	 that	 allows	 blood	 circulation,	 and	 the	 lymphatic	 system,	 a	 blind-ended	 tubular	




specialized	 endothelial	 cells	 (ECs),	 major	 differences	 exist	 in	 the	 anatomy	 of	 the	 vascular	
wall.		
Arteries	 and	 veins	 display	 distinct	 and	 unique	 architectures,	 adapted	 to	 their	 respective	
functions.	As	blood	is	pumped	into	the	arteries	with	a	high	pressure	and	flow	rate,	the	walls	
of	the	main	conductance	arteries,	 i.e.	aorta	and	carotid	arteries,	are	very	thick	and	elastic.	
On	 a	 cross-section	 three	 different	 layers	 can	 be	 discerned:	 the	 tunica	 intima,	 the	medial	
tunica	media	and	the	tunica	adventitia.	The	large	arteries	are	elastic;	in	physiological	terms	







that	 are	 highly	 responsive	 to	 vasoactive	 substances;	 they	 are	 therefore	 often	 called	
contractile	 smooth	 muscles	 as	 opposed	 to	 the	 synthetic	 smooth	 muscles	 found	 in	 the	
conductance	arteries.	 Smooth	muscle	 cells	 in	 resistance	arteries	express	 various	 receptors	
including	 alpha-adrenergic	 receptors,	 angiotensin-II	 receptors	 and	 endothelin	 receptors,	
enabling	contractile	responses	to	circulating	 levels	of	the	corresponding	 ligands	(Rensen	et	
al.	 2007).	 Endothelial	 cells	 of	 resistance	 arteries	 can	 furthermore	 produce	 substantial	
amounts	of	 vasodilator	 substances	 including	nitric	oxide	and	prostaglandins.	By	 regulating	
the	vascular	tone	via	the	amount	of	vasoconstrictors	and	-dilators,	the	resistance	to	flow	and	
organ	 perfusion	 can	 be	 precisely	 fine-tuned.	 In	 addition,	 resistance	 arteries	 are	 often	
innervated	by	sympathetic	nerves	allowing	central	control	of	organ	perfusion	(Charkoudian	
&	 Rabbitts	 2009).	 More	 distal	 and	 within	 the	 organs	 blood	 flow	 is	 distributed	 by	 small	
arterioles,	which	 typically	display	a	media	consisting	of	 two	 layers	of	 smooth	muscle	cells.	
Besides	expressing	receptors	for	vasoactive	molecules,	arterioles	are	highly	sensitive	to	local	
changes	 in	 metabolism	 such	 as	 tissue-specific	 partial	 pressure	 of	 oxygen	 (pO2)	 and	 local	
hemodynamics	 including	 pressure	 and	 flow	 (Pittman	 et	 al.	 2005).	 Typically,	 a	 local	 rise	 in	
arteriolar	 pressure	 evokes	 a	myogenic	 constriction,	whereas	 increases	 in	 flow	 or	 low	 pO2	








pressure	 in	 the	 veins	 is	 low,	 and	 thus	 their	 wall	 is	 comparably	 thinner	 with	 venous	 flow	
directionality	 being	 ensured	 via	 venous	 valves	 preventing	 a	 reflux.	 Yet,	 veins	 are	 very	
compliant	and	they	serve	to	store	considerable	amounts	of	blood	in	resting	conditions.	Thus,	
the	 blood	 vessels	 have	 a	 hierarchical	 structure	 with	 arteries	 and	 veins	 as	 main	 vessels	
carrying	large	blood	volumes.	These	are	connected	to	arterioles	and	venules	with	a	smaller	
diameter	 and	 thinner	 vessel	 walls,	 which	 eventually	 branch	 into	 to	 the	 highly	 ramified	
network	of	thin	collaterals	to	distribute	the	blood	(Figure	1)	(Carmeliet	2000).	
Vessels	 can	 adapt	 their	 structure,	 lumen	 diameter	 and	 media	 thickness	 in	 response	 to	
hemodynamic	 changes.	 In	 general,	 increases	 in	 flow	 associate	 with	 vessel	 dilation	 and	
structural	outward	remodelling,	yielding	a	vessel	with	a	structurally	larger	lumen.	Increases	
in	 pressure,	 at	 the	 level	 of	 arterioles,	 associate	 with	 a	 myogenic	 constriction	 occurring	
acutely	upon	pressure	rise,	whereas	long	term	increases	in	pressure	associate	with	a	thicker	
media	 and	 remodelling	 of	 the	 media	 around	 smaller	 lumen,	 collectively	 reducing	 vessel	
diameter	and	 increasing	resistance	to	flow.	Vessels	also	adapt	to	changes	 in	the	metabolic	
demand	of	the	tissue	they	are	supplying.	It	is	well	known	that	physical	exercise,	via	increases	
in	 muscle	 metabolism,	 promotes	 angiogenesis	 of	 new	 capillaries	 around	 muscle	 fibers,	
whereas	 long-term	 inactivity	 associates	 with	 vessel	 regression	 (Hoier	 &	 Hellsten	 2014).	
However,	 the	 quality	 and	 quantity	 of	 these	 adaptive	mechanisms	 vary	 among	organs,	 yet	
they	 appear	 optimized	 for	 organ	 function.	 For	 example,	 post-capillary	 venules	must	 allow	
circulating	leukocytes	to	enter	the	lymph	node,	but	the	cerebral	vasculature	is	tightly	sealed	
to	 prevent	 leakage	 of	 serum	 proteins	 and	 cells	 at	 the	 blood	 brain	 barrier	 (Tam	 &	Watts	
2010).	 One	 of	 the	 major	 outstanding	 questions	 in	 the	 field	 is	 how	 tissues	 controls	 the	
distinct	 vascular	 properties	 including	 vascular	 diameter,	 vascular	 reactivity,	 branching	
patterning,	 and	 transport	 capacity	 (Corada	 et	 al.	 2014).	 Little	 is	 known	 about	 how	 this	 is	
genetically	hardwired,	but	evidence	 is	emerging	suggesting	an	 intimate	cross-talk	between	











signalling	 and	 hemodynamics.	 To	 become	mature	 and	 stable,	 blood	 vessels	 subsequently	
need	 to	 adapt	 their	morphology	 to	 the	 blood	 flow	 they	 are	 carrying.	 During	 this	 vascular	
remodelling	 process	 their	 diameter	 enlarges,	 and	 later	 smooth	 muscle	 cells	 (SMCs)	 and	
pericytes	are	recruited	to	the	vessel	wall	(Carmeliet	2000;	Carmeliet	&	Collen	2000).	



















ventrally	 to	 the	 notochord	 (NC)	 (Figure	 2),	 are	 lumenized	 at	 approximately	 23	 hours	 post	
fertilization	 (hpf)	 with	 circulation	 starting	 shortly	 thereafter.	 The	 trunk	 vasculature	
furthermore	 consists	 of	 arterial	 and	 venous	 intersegmental	 vessels	 (aISVs	 and	 vISVs,	
respectively).	The	aISVs	start	emerging	via	sprouting	angiogenesis	bilaterally	from	the	DA	at	
around	20hpf	in	a	process	termed	primary	sprouting	(Figure	2i)	(Isogai	et	al.	2003),	growing	
dorsally	within	 the	 somatic	boundaries	 along	 the	NC	and	 the	neural	 tube	 (NT)	 (Figure	2i).	
Once	 the	 ISVs	 have	 reached	 the	 dorsal	 roof	 plate	 of	 the	 NT,	 one	 branch	 grows	
perpendicularly	 in	 the	 rostral,	 the	 other	 one	 in	 the	 caudal	 direction	 (Figure	 2ii).	 The	
perpendicular	vessel	branches	of	adjacent	 ISVs	bilaterally	 form	anastomoses,	giving	rise	 to	
the	dorsal	 longitudinal	 anastomotic	 vessel	 (DLAV)	at	appr.	1.5dpf	 (Figure	2iii)	 (Isogai	et	al.	
2003).	 This	 process	 was	 suggested	 to	 be	 supported	 by	 tissue	macrophages	 interacting	 as	
“cellular	 chaperones”	with	 EC	 filopodia	 to	 help	 the	 vessel	 fusion,	 but	 detailed	 studies	 are	
missing	 (Fantin	et	al.	2010).	As	a	vascular	 loop	 is	needed	 for	 the	blood	 to	circulate,	 in	 the	
next	 step	 of	 vascularization	 veins	 are	 formed	 in	 a	 process	 called	 secondary	 sprouting.	
Vessels	 emerge	 bilaterally	 from	 the	 PCV,	 grow	 again	 within	 the	 somitic	 boundaries	 and	
elongate	 towards	 the	 primary	 aISVs	 (Figure	 2iv-v).	 About	 half	 of	 the	 secondary	 sprouts	
connect	with	 the	primary	 ISV,	 the	 remaining	arterial	 connections	detach	and	dissolve,	and	
thereby	the	aISVs	become	veins.	The	other	half	of	the	secondary	sprouts	elongates	towards	
the	horizontal	myoseptum	 (HM),	where	 the	 sprouts	 branch	 rostrally	 and	 caudally	 to	 form	








(vi)	 finally	 50%	 fuse	 to	 a	 primary	 aISV,	 resulting	 in	 a	 vISV.	 The	 other	 50%	 form	 a	 lymphatic	 vessel.	 Right:	
Compartments	 of	 the	 zebrafish	 trunk.	 DA,	 dorsal	 aorta;	 DLAV,	 dorsal	 longitudinal	 anstomotic	 vessel;	 ISV,	






tumourigenesis,	 when	 Judah	 Folkman	 discovered	 the	 dependence	 of	 tumour	 growth	 on	
blood	vessel	supply,	and	the	secretion	of	pro-angiogenic	factors	by	tumours	(Folkman	et	al.	
1971).	 Folkman	was	among	 the	 first	 to	 recognize	 that	many	pathologies	 including	 tumour	
growth	 are	 related	 to	 uncontrolled	 angiogenesis.	 As	 diseases	 associated	 with	 excessive	
angiogenesis	 can	 principally	 affect	 any	 vascularised	 organ,	 the	 disease	 pictures	 are	 very	
heterogeneous,	 including	for	example	arthritis,	psoriasis,	primary	pulmonary	hypertension,	
and	 inflammatory	 bowel	 disease	 (Carmeliet	 2003).	 	 The	 reverse	 is	 also	 true:	 Devastating	
diseases	 including	hypertension	and	diabetes	associate	with	vessel	pruning	and	 regression	
(Korn	 &	 Augustin	 2015).	While	 in	 the	 context	 of	 tumour	 growth	 it	 is	 beneficial	 to	 inhibit	
vascular	 growth,	 several	 other	 medical	 conditions	 may	 improve	 when	 vascular	 growth	 is	
stimulated.	 For	 example	 in	 the	 case	 of	 many	 ischemic	 cardiovascular	 diseases	 like	 heart	
infarct	 and	 stroke	 revascularization	 strategies	 are	 considered	 to	 improve	 the	 clinical	
outcome.	 Unfortunately,	 many	 clinical	 trials	 aiming	 at	 stimulating	 functional	
Introduction 
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revascularization	 in	 the	 ischemic	 setting	 have	 failed	 and	 more	 research	 is	 needed	 to	
understand	the	fundamental	principles	of	building	stable	and	perfused	networks.	
Formation	of	blood	vessels	in	the	embryo	shows	many	molecular	and	functional	similarities	
with	 vessel	 growth	 in	 pathological	 conditions	 in	 the	 adult.	 Therefore,	 deciphering	 the	
molecular	mechanisms	contributing	 to	vascular	growth	during	embryogenesis	may	help	 to	
identify	 therapeutic	 targets.	 Recent	 research	 addressing	 growth	 in	 zebrafish	 embryos	 and	
foetal/	 neonatal	 mice	 identified	 several	 novel	 aspects	 to	 angiogenesis	 crucial	 for	 making	
functional	networks.	These	include	the	formation	of	additional	branches	or	vessel	segments	




migrate	 out	 of	 the	 existing	 vessel	 to	 initiate	 the	 sprout.	 Subsequently,	 this	 sprout	 has	 to	
elongate	in	a	unidirectional	manner.	Thus,	two	different	cell	types	participate	in	SA,	namely	
tip	and	stalk	cells.	Tip	cells	are	migratory,	polarized	cells	at	 the	 leading	 front	of	a	growing	












While	patients	with	microvascular	defects	 affecting	 arterioles,	 venules	 and	 capillaries	may	









small-diameter	 to	 large-diameter	 collateral	 arteries,	 a	 process	 called	 arteriogenesis	
(Cristofaro	et	al.	2013).	




comprehend	 first	 the	 initial	 lumen	 formation	 in	 a	 newly	 formed	 capillary,	 i.e.	 the	
transformation	 from	 a	 cord-like	 EC	 chain	 to	 a	 tubular	 vessel.	 Similar	 to	 sprouting	
angiogenesis,	the	embryonic	zebrafish	ISVs	constitute	a	valuable	model	to	study	this	process	
in	vivo.	To	date,	three	different	theories	on	the	process	of	capillary	lumenization	have	been	
put	 forward	 in	 the	 zebrafish	 ISVs,	 which	 constitute	 an	 ideal	 model	 to	 study	 this	 initial	
capillary	lumen	formation.		
One	of	these	theories	describes	luminal	space	formation	via	endothelial	vacuoles	(Kamei	et	
al.	 2006).	 It	 was	 suggested	 that	 vesicles	 emerge	 via	 fluid	 endocytosis,	 also	 known	 as	








al.	 (2016)	 introduced	 inverse	 blebbing	 as	 hemodynamics-coupled	 mechanism	 of	 lumen	
expansion	 in	 the	 tip	 of	 angiogenic	 sprouts.	 They	 suggest	 that	 the	 prevalence	 of	 a	 higher	
pressure	at	the	 luminal	compared	to	the	cytoplasmic	site	causes	a	 local	actomyosin	cortex	
weakening	 and	 a	 subsequent	 inverse	 membrane	 blebbing	 (Figure	 3d).	 The	 bleb	 is	
consequentially	 resolved	by	 actomyosin	 contraction	of	 the	 apical	membrane,	 and	 thereby	





capillaries	 such	 as	 the	 zebrafish	 ISVs	 is	 not	 completely	 understood	 so	 far,	 and	most	 likely	
different	 vascular	 beds	 and	 developmental	 stages	 exploit	 distinct	 lumen	 formation	
mechanisms	(Betz	et	al.	2016).		
A	 recent	 in	 vitro	 study	 reported	 the	 involvement	 of	 lateral	 filopodia	 in	 lumen	 formation	
(Abraham	 et	 al.	 2015).	 The	 authors	 propose	 a	 model	 in	 which	 VEGF-A	 –	 KDR	 signalling	
induces	 a	 DOCK4/DOCK9/Cdc42	 complex	 that	 initiates	 filopodia	 protrusions,	 which	 form	   







Depiction	 of	 a	 multicellular	 ISV	 with	 in	 extracellular	 lumen	 between	 adjacent	 ISVs.	 (c)	 Concept	 of	 lateral	
filopodia	formation,	leading	to	EC-EC	contacts.	Subsequently,	an	interendothelial	lumen	is	formed.	(d)	Inverse	








Most	 mammalians	 possess	 a	 native	 collateral	 network,	 which	 is	 a	 bypass	 vasculature	
between	arterial	trees	serving	as	a	sort	of	“backup	system”	to	preserve	blood	flow	in	case	of	
arterial	 occlusion	 in	 one	 of	 the	 trees.	 Microvascular	 collaterals	 are	 arteriole-to-arteriole	
anastomoses	in	arterial	tree	crowns	with	the	capacity	to	enlarge	up	to	10-fold	upon	arterial	
occlusion;	collateral	arteries	are	connections	between	feed	arteries	(Faber	et	al.	2011).	
The	 outcome,	 that	means	 the	 severity	 of	 the	 tissue	 damage,	 of	 acute	 or	 chronic	 arterial	
obstructions	varies	widely	among	individuals,	which	can	be	explained	by	differences	in	their	
endogenous	 backup	 system,	 i.e.	 in	 their	 collateral	 extent.	 Parameters	 determining	 the	
collateral	 extent	 are	 collateral	 number	 and	 diameter	 (Faber	 et	 al.	 2014).	 Measuring	
collateral	flow	in	humans	revealed	variations	by	the	factor	40,	and	those	patients	with	a	low	
collateral	 flow	 had	 an	 increased	 risk	 of	 mortality	 when	 suffering	 from	 coronary	 artery	
disease.	The	native	collateral	network	is	mainly	determined	by	genetic	factors,	and	recently	
a	genetic	locus	important	for	collateral	extent	was	discovered	in	mice	(Sealock	et	al.	2014).	
With	 age,	 the	 collateral	 extent	 is	 decreasing	 (Faber	 et	 al.	 2011).	 However,	 not	 only	 the	





difference	 in	 the	 collaterals;	 as	 a	 consequence	 there	 is	 increased	 collateral	blood	 flow,	an	
event	known	as	collateral	recruitment	(Faber	et	al.	2014).	
	
The	 resulting	 shear	 stress	 increase	 induces	 a	 vascular	 remodelling	 process	 known	 as	
arteriogenesis	 including	 diameter	 enlargement	 and	 vessel	 wall	 thickness	 increase.	
Confusingly,	 in	 the	 literature	 the	 original	 definition	 of	 arteriogenesis	 has	 been	 frequently	
overlooked	and	the	term	has	been	adapted	for	a	variety	of	other	processes,	for	example	to	
describe	 the	developmental	process	of	 vessel	maturation,	which	occurs	 after	 vessels	have	
been	 formed	 by	 angiogenesis	 and	 lumenization	 has	 occurred.	 During	 this	 maturation	
process,	smooth	muscle	cells	 (SMCs)	and	pericytes	are	recruited	to	muscularize	the	vessel,	





There	 are	 four	 phases	 of	 collateral	 remodelling	 into	 mature	 conductance	 arteries	 after	
arterial	occlusion	(Schaper	2009).	In	the	first	phase,	the	silent	phase,	ECs	sense	the	saltatory	
shear	 stress	 increase,	which	has	 to	be	communicated	 to	 the	SMCs.	Thus,	 cell-cell	 contacts	
are	 highly	 important	 for	 outward	 remodelling.	 	 ECs	 and	 SMCs	 undergo	 a	 change	 in	 their	
phenotype;	 the	 endothelium	 becomes	 more	 permeable,	 the	 contractile	 SMCs	 become	




and	 SMCs.	 Blocking	 any	 of	 these	 molecules	 abrogates	 arteriogenesis,	 highlighting	 that	
arteriogenesis	 is	 dependent	 on	 the	 concerted	 effort	 of	 different	 factors.	 In	 the	 second	
phase,	macrophages	are	attracted,	infiltrate	the	vessel	wall	and	secrete	proteases	to	digest	
the	 extracellular	 scaffold	 in	 order	 to	 clear	 space	 for	 the	 collateral	 enlargement	 (Schaper	
2009).	ECs	upregulate	platelet-derived	growth	factor	(PDGF)-B,	basic	fibroblast	growth	factor	
(bFGF)	 and	 transforming	 growth	 factor	 (TGF)-β1	 to	 induce	 EC	 and	 SMC	proliferation	 and	
thus	vessel	diameter	 increase	 (Carmeliet	2000).	Vessel	maturation	 takes	place	 in	 the	 third	
phase.	The	large	number	of	SMCs	arrange	in	layers,	integrins	and	connexins	are	upregulated	
to	establish	proper	cell-cell	contacts	and	the	extracellular	scaffold	is	rebuilt	(Schaper	2009).	
In	 the	 last	 phase,	 unneeded	 vessels	 undergo	 pruning,	 and	 they	 are	 sealed	 by	 intimal	
proliferation.	
	
The	 stimulation	 of	 arteriogenesis	with	 growth	 factors	 has	 been	 attempted	 in	 a	 variety	 of	
studies.	The	involvement	of	FGF	receptor	(FGFR)-1	in	arteriogenesis	awakened	the	hope	that	
FGF	 might	 be	 exploited	 as	 therapeutic	 target	 to	 stimulate	 arteriogenesis.	 However,	 the	
stimulation	 with	 FGF	 is	 much	 more	 difficult	 than	 anticipated	 as	 many	 FGF	 ligands	 exist,	
which	probably	contribute	to	arteriogenesis	in	a	joint	effort	(Schaper	2009).	With	respect	to	
VEGF-A,	 its	 pharmacological	 blockade	 inhibits	 arteriogenesis,	 but	 VEGF-A	 administration	
could	 not	 completely	 restore	 flow	 and	many	 clinical	 trials	 did	 not	 result	 in	 the	 hoped-for	




Taken	 together,	 although	 pro-arteriogenic	 therapeutic	 strategies	 have	 been	 pursued	 for	
decades,	 these	 attempts	 have	 been	 of	 little	 success	 so	 far	 (van	 Royen	 et	 al.	 2009).	 As	




Figure 4| Collateral circulation.	
(a)	 The	 native	 collateral	 network	 is	 already	 formed	 during	 embryogenesis,	 and	 the	 collateral	 extent	 is	
determined	by	genetic	factors.	(b)	Collaterals	connect	two	arterial	trees.	(c)	Upon	occlusion	of	one	of	the	trees,	
flow	 increases	 in	 the	 collaterals	 to	 reroute	 the	 occluded	 site,	 a	 process	 termed	 collateral	 recruitment.	 (d)	
Increased	 shear	 stress	 levels	 in	 the	 collaterals	 induce	 the	 outward	 remodelling	 of	 the	 collaterals,	 known	 as	
arteriogenesis.	 (e)	 Neo-collateral	 formation	 is	 pursued	 in	 many	 different	 therapeutic	 strategies	 in	 order	 to	















&	 Schlessinger	 2010).	 Upon	 dimerization,	 the	 VEGF	 receptors	 are	 internalized,	 followed	
either	by	degradation	or	recycling	to	the	membrane	(Simons	et	al.	2016).	The	VEGF	ligands	
can	be	classified	according	to	the	receptors	they	are	binding	to	(Figure	5).	VEGF-A,	or	simply	
VEGF,	 is	 the	key	player	 in	angiogenesis	and	can	bind	 to	both	VEGF	receptor	 (VEGFR)-1	 (or	
FLT1)	 and	 VEGFR-2	 (or	 KDR,	 FLK1).	 Placental	 growth	 factor	 (PlGF)	 and	 VEGF-B	 exclusively	
bind	to	FLT1.	VEGF-C	and	–D	are	the	ligands	of	VEGFR-3	(FLT4),	and	processed	forms	of	these	
ligands	can	also	bind	to	KDR.	The	virus-expressed	VEGF-E	exclusively	binds	to	KDR	(Ferrara	et	




and	 -2,	 which	 are	 composed	 of	 a	 large	 extracellular	 ligand-binding	 domain,	 a	
transmembrane	 domain	 and	 a	 cytoplasmic	 domain	 with	 a	 PDZ	 protein-binding	 domain.	
NRP1	 is	mainly	 a	 co-receptor	 of	 KDR,	 NRP2	 of	 VEGFR3	 (Koch	&	 Claesson-Welsh	 2012).	 In	
addition,	 they	 can	 act	 as	 VEGF	 ligand	 sink.	Whether	 they	 can	 signal	 remains	 a	matter	 of	
debate	(Snuderl	et	al.	2013;	Simons	et	al.	2016).	
	
In	zebrafish,	 the	KDR	ortholog	 is	kdr-like	 (kdrl),	also	known	as	kdrb	 (Bussmann	et	al.	2008;	
Covassin	et	al.	2009).	Due	to	the	genome	duplication	there	are	two	paralogs	of	vegfa,	with	









The	 VEGF	 family	 consists	 of	 the	 three	 receptors	 VEGFR-1,	 -2	 and	 -3,	which	 are	 forming	 dimers	 upon	 ligand	
binding.	 Their	 diverse	 functions	 are	 partly	 derived	 from	 their	 differential	 ligand	 binding	 profile.	 The	
co-receptors	NRP-1	and	-2	can	in	addition	aid	in	VEGF	receptor	signalling.	The	majority	of	angiogenic	signalling	












is	 contradictory	 to	 the	 current	 tip	 cell	 concept,	 which	 is	 based	 on	 the	 assumption	 that	
vascular	 flt1	 is	 crucial	 for	 proper	 vessel	 sprouting.	 According	 to	 this	 concept,	 flt1	 is	
upregulated	by	Dll4	–	Notch	signalling	in	stalk	cells	to	form	an	antiangiogenic	corridor,	while	
the	tip	cell	is	void	of	flt1,	resulting	in	a	“salt	and	pepper”	expression	pattern	(Chappell	et	al.	
2009;	 Herbert	 &	 Stainier	 2011).	 As	 we	 found	 that	 Flt1	 is	 not	 required	 for	 sprouting	
Introduction 
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angiogenesis	 (Wild	 et	 al.	 2017),	 the	proposed	expression	pattern	 is	 questionable.	Another	
expression	 domain	 of	 Flt1	 are	macrophages	 (Clauss	 et	 al.	 1996;	 Sawano	 et	 al.	 2001),	 and	
during	gestation	particularly	sFlt1	is	expressed	in	trophoblasts	(Fan	et	al.	2014).	While	Flt4	is	
expressed	 in	 all	 blood	 vessel	 ECs	 in	 early	 developmental	 stages,	 its	 expression	 becomes	
restricted	 to	 venous	 and	 lymphatic	 ECs	 in	mice	 and	 zebrafish	 (Kaipainen	 et	 al.	 1995;	 van	
Impel	et	al.	2014).	
In	 zebrafish,	vegfaa	 is	expressed	 in	 the	somites	 in	early	development	 (Jensen	et	al.	2015),	
and	 we	 could	 show	 that	 vegfaa	 is	 furthermore	 expressed	 in	 neurons	 (Wild,	 Klems	 et	 al.	
2017).	 Given	 the	 fact	 that	 the	 function	 of	 vascular	 Flt1	 in	 vessel	 development	 is	 not	
understood	yet,	 it	 is	surprising	how	little	attention	has	been	paid	to	the	role	of	 its	specific	
ligands	 PlGF	 and	 VEGF-B.	 A	 fundamental	 first	 step	 herein	 would	 be	 to	 understand	 their	
developmental	expression	patterns.	This	 lack	of	studies	 is	presumably	due	to	 the	 fact	 that	
Plgf	 expression	 has	 been	 described	 as	 neglectable	 during	 development	 and	 health	
(Carmeliet	 et	 al.	 2001),	 with	 the	 exception	 of	 pregnancy	 where	 Plgf	 is	 expressed	 in	
trophoblasts	 and	placental	 villi	 (Dewerchin	&	Carmeliet	 2012).	 In	 contrast,	 various	 studies	




disease	 conditions	 would	 not	 have	 a	 function	 in	 the	 greatest	 remodelling	 process,	 i.e.	 in	
embryonic	vascular	development.	A	detailed	analysis	of	Plgf	expression	domains	would	be	
critical	 to	 fully	 understand	 its	 mechanism	 of	 action.	 Due	 to	 its	 upregulation	 in	 disease	
conditions,	PlGF	 is	 regarded	as	a	potential	biomarker	 in	 the	clinic.	For	example	 in	patients	













VEGF-A	 –	 KDR	 signaling	 is	 the	 major	 mediator	 of	 EC	 biology	 in	 developmental	 and	
pathological	 conditions,	 including	 cell	 differentiation,	 migration,	 proliferation	 and	 tube	
formation	 (Koch	&	 Claesson-Welsh	 2012).	 The	 significance	 of	 this	 pathway	 for	 angiogenic	
development	becomes	obvious	 in	 light	of	the	fact	that	the	Vegfa	gene	 is	haploinsufficient;	





to	 be	 tightly	 regulated	 by	 numerous	 inducers	 as	 well	 as	 negative	 feedback	 loops	 for	 the	




Vegfa	mRNA	 levels	 in	 conditions	with	 low	oxygen	 tension.	Under	normoxic	 conditions	 the	
Hif1α	 subunit	 is	 hydroxylated,	 enabling	 the	 binding	 to	 the	 E3	 ubiquitin	 ligase	 von	Hippel-







the	VEGF-A	accessibility	 for	KDR	binding	 is	mediated	by	 the	capacity	of	VEGF-A	 to	diffuse.	
The	diffusibility	of	the	different	VEGF-A	isoforms	depends	on	the	presence	of	a	basic	amino	
acid	stretch,	which	allows	binding	to	NRPs	and	to	heparan	sulphate	in	the	ECM.	VEGF-A121	









ways.	 Intensity	 and	 duration	 of	 KDR	 signalling	 is	 mainly	 regulated	 by	 the	 rate	 of	 KDR	
internalization,	degradation	and	recycling	 (Koch	&	Claesson-Welsh	2012).	One	regulator	of	
KDR	 internalization	 is	 NRP1,	 acting	 as	 KDR	 adaptor	 protein.	When	 VEGF-A	 –	 NRP1	 –	 KDR	
complexes	are	formed	in	cis,	 i.e.	on	the	same	cell	membrane,	NRP1	binds	with	its	cytosolic	
PDZ-binding	 domain	 to	 PDZ	 domain-containing	 adaptor	 proteins	 and	 mediates	 the	
endosomal	translocation	of	KDR.	On	the	other	hand,	NRP1	associated	in	trans	with	KDR,	i.e.	
on	 adjacent	 cells,	may	 be	 antiangiogenic	 as	 it	 prevents	 KDR	 internalization	 (Simons	 et	 al.	











of	 PI3K	 induces	 AKT	 phosphorylation,	 important	 for	 EC	 survival,	 vessel	 maturation	 and	
metabolism.	AKT	 can	 furthermore	activate	eNOS	 to	 trigger	NO	production	 in	 the	adjacent	





VEGFR-1	 (Flt1)	 has	 a	 membrane-bound	 (mFlt1)	 and	 a	 soluble	 form	 (sFlt1),	 which	 are	





Flt1	 prevents	 venous	 hypersprouting	 at	 the	 spinal	 cord	 in	 zebrafish	 by	 scavenging	 Vegfaa	




Whether	 mFlt1	 is	 not	 only	 a	 VEGF-A	 sink	 but	 possesses	 the	 capacity	 to	 signal	 is	
controversially	 discussed.	 In	 embryonic	 sprouting	 angiogenesis	 mFlt1	 signalling	 is	 not	
important,	as	Flt1TK-/-	mice	without	the	tyrosine	kinase	domain	and	mflt1-/-	zebrafish	do	not	




ISV	growth.	A	mutated	 form	of	Plgf	 incapable	of	binding	 to	Flt1	 is	not	able	 to	 restore	 the	
vasculature	in	vegfaa-/-	mutants,	 indicating	that	the	rescue	was	due	to	Plgf	–	Flt1	signalling	
(Rossi	 et	 al.	 2016).	 However,	 most	 studies	 on	 mFlt1	 signalling	 report	 a	 function	 in	
macrophage	chemoattraction	(Murakami	et	al.	2006;	Shibuya	2006).	
Regarding	 Flt1	 downstream	 signalling,	 VEGF-A	 and	 PlGF	 cause	 the	 phosphorylation	 of	
different	tyrosine	residues,	suggesting	different	downstream	activation	pathways	of	the	two	




homodimer	 phosphorylation	 by	 inducing	 its	 transphoshorylation	 via	 the	 Flt1	 homodimer	
(Autiero	 et	 al.	 2003).	However,	 the	 data	 on	 such	 a	 transphosphorylation	 are	 very	 limited,	
questioning	 the	occurrence	of	 such	 a	 transphosphorylation	 in	 vivo.	With	 respect	 to	 Flt1	 –	
VEGF-B	signalling	a	recent	study	on	Flt1	receptor	conformation	upon	PlGF	or	VEGF-B	binding	
could	 show	 that	 the	 two	 ligands	bind	 to	different	 Flt1	 immunoglobulin	 (Ig)	 domains.	Only	
PlGF	binding	 induced	an	 “activated”	 Flt1	dimer	 conformation	 in	which	 its	 tyrosine	 kinases	
are	close	enough	for	transphosphorylation,	whereas	VEGF-B	binding	did	not	evoke	such	an	









(Maglione	et	al.	1991).	PlGF	has	 four	 isoforms	 in	humans	derived	 from	alternative	splicing	
with	PlGF-1	and	-3	being	diffusible	and	PlGF-2	and	-4	containing	a	heparin	binding	domain	
enabling	 the	 binding	 to	 the	 receptors	 NRP1	 and	 -2	 and	 to	 heparan	 sulphate.	 Mice	 and	
zebrafish	express	a	single	isoform	(Dewerchin	&	Carmeliet	2012;	Rossi	et	al.	2016).	
PlGF	 was	 described	 as	 an	 important	 factor	 during	 the	 angiogenic	 switch	 in	 disease	
(Dewerchin	&	Carmeliet	2012),	therefore	most	studies	have	focussed	on	PlGF	in	pathological	




that	 a	 big	 flaw	 of	 the	 last	 decades	 of	 PlGF	 research	 was	 the	 lack	 of	 an	 in-depth	





As	 a	 first	 step	of	 sprouting	 angiogenesis,	 an	 endothelial	 cell	 of	 an	 existing	 vessel	must	 be	
activated	to	become	a	tip	cell.	This	occurs	via	VEGF-A	–	KDR	signalling.	To	prevent	 that	all	
ECs	 become	 a	 tip	 cell,	 the	 Dll4	 –	 Notch	 signalling	 suppresses	 the	 tip	 cell	 fate	 via	 lateral	
inhibition	 according	 to	 the	 tip-stalk	 cell	 model.	Dll4	 is	 upregulated	 by	 KDR	 signalling	 and	
induces	Notch	signalling	 in	 the	adjacent	cell.	Notch	signalling	 then	downregulates	 the	pro-





However,	according	to	this	model	Flt1	has	 to	be	expressed	 in	a	“salt	and	pepper”	 fashion,	
but	substantial	in	vivo	data	on	Flt1	distribution	is	missing	to	date.	Another	concept	on	sprout	
initiation	 involves	 the	 formation	of	an	 sFlt1	 “corridor”	 to	allow	 the	activation	of	VEGF-A	–	










Hemodynamic	 forces	 are	 main	 mediators	 of	 vessel	 architecture	 adaption	 to	 variations	 in	
blood	flow,	which	in	turn	reflect	changes	in	metabolic	needs.	Three	forces	acting	on	a	blood	







that	 the	 energy	 to	 produce	 the	 blood	 volume	 that	 is	 pumped	 through	 a	 vessel	 is	
proportional	to	the	energy	of	the	actual	blood	pumping	process	through	that	vessel	(Painter	
et	 al.	 2006).	 According	 to	 Murray’s	 law,	 the	 optimum	 of	 these	 energies	 is	 reached	 in	 a	
branched	vasculature,	if	the	relation	between	the	radius	of	a	parent	vessel	(rp)	upstream	of	a	
branch	and	the	radius	of	the	downstream	daughter	vessels	(rd)	conforms	to	rp3=	rd13+	rd23.	
Another	 important	 haemodynamic	 law	 is	 from	Poiseuille,	 describing	 the	 relation	 between	
hydraulic	resistance,	blood	vessel	length,	radius	and	blood	viscosity	(Figure	6a).	As	the	latter	









Shear	 stress	 evokes	 fast	 cellular	 responses,	 including	 the	 flow-sensitive	 ion	 channel	
activation,	 changes	 in	 the	 intracellular	 pH	 and	 induction	 of	 Ca2+	 fluxes	 in	 the	 cell;	
subsequently,	the	activation	of	different	pathways	induces	specific	gene	expression	profiles,	
which	 ultimately	 lead	 to	 cytoskeletal	 reshaping	 and	 vascular	 remodelling	 (Mazzag	 et	 al.	
2003).	Recent	studies	could	show	that	also	VEGFR-	and	-3	were	involved	in	mechanosensory	
complexes	 (Baeyens	&	Schwartz	2016).	According	 to	 the	 shear	 stress	 set	point	 theory	any	
shear	 stress	 above	 a	 certain	 range	 induces	 outward	 remodelling,	 whereas	 a	 lower	 shear	
stress	 results	 in	 inward	 remodelling	 (Baeyens	 &	 Schwartz	 2016).	 However,	 the	 gene	
expression	 profile	 varies	 with	 the	 type	 of	 shear	 stress	 acting	 on	 a	 vessel.	 Atherosclerotic	
plaques,	 for	example,	develop	 in	 regions	of	oscillatory	and	 low	shear	stress,	whereas	such	
wall	 thickening	 is	 rare	 in	vessels	of	high,	constant	shear	stress	 (Mazzag	et	al.	2003).	 In	the	
ECs	 in	 atherosusceptible	 regions,	 however,	 a	 reduced	 expression	 level	 of	 the	 protective	
























the	mouse	 skin	 it	 was	 shown	 that	 peripheral	 sensory	 nerves	mediate	 arteriogenesis,	 and	
sensory	axons	dictate	the	path	of	artery	vessels	(Mukouyama	et	al.	2002).	Also	sympathetic	
nerves	 promoted	 arterial	 differentiation	 (Pardanaud	 et	 al.	 2016).	 In	 addition,	 perivascular	
nerves	 are	 involved	 in	 the	 regulation	 of	 the	 vascular	 tone	 by	 releasing	 vasoconstrictive	
substances	(Burnstock	&	Ralevic	1994).	
At	 the	molecular	 level,	 nerves	 and	 vessels	 are	both	guided	by	attractive	or	 repulsive	 cues	
(Lowery	&	Van	Vactor	2009),	and	 they	even	share	some	guidance	 factors	 (Eichmann	et	al.	
2005).	Such	factors	with	a	dual	function	in	axon	and	vessel	guidance	are	called	angioneurins	
(Carmeliet	&	Tessier-Lavigne	2005).	As	all	four	classical	axon	guidance	families	were	found	to	
be	 angioneurins,	 the	 question	 arose	 whether	 the	 reverse	 is	 also	 true	 for	 the	 classical	
angiogenesis	proteins,	i.e.	if	the	VEGF	family	has	functions	in	the	neuronal	system	(Carmeliet	
&	Tessier-Lavigne	2005).	Recently,	we	found	that	several	Vegf	receptors,	 including	flt1	and	
kdrl	 and	Vegf	 ligands	 including	vegfaa	 and	plgf	 are	expressed	 in	motoneurons	 (Wild	et	al.	
2017).	While	neuronal	Flt1	has	the	function	to	limit	sprouting	at	the	neural	tube,	the	role	of	
the	ligands	in	neuronal	development	remains	unclear	so	far.	
With	 respect	 to	 sensory	 nerve-derived	 VEGF-A	 it	 is	 known	 that	 it	 is	 involved	 in	 arterial	
differentiation	in	the	mouse	skin	(Mukouyama	et	al.	2002).	In	addition,	VEGF-A	was	reported	
to	 be	 important	 for	 motoneurons,	 as	 VEGF-A	 could	 ameliorate	 the	 symptoms	 of	 the	






the	 studies	 on	 the	 Vegf	 ligands	 in	 neuronal	 development	 are	 relatively	 poor,	 a	 detailed	






























	(a,b)	 The	 drawing	 from	 anatomist	
Vesalius	depicts	that	nerves	and	vessels	
both	 consist	 of	 highly	 branched	
networks.	 (c)	Confocal	 image	of	aligned	
vessels	 in	 red	 and	 nerves	 in	 green.	








of	 the	 flt1	 promoter	 activity	 as	well	 as	mflt1	 and	 sflt1	 expression	 by	whole-mount	 in	 situ	
hybridization	 (WISH)	 revealed	 flt1	 expression	 in	 the	 aorta,	 arterial	 ISVs	 and	 remodelled	
artery-derived	 venous	 ISVs.	 In	 addition,	 analysis	 in	 flt1	 reporter	 embryos	 and	 RNAseq	
analysis	 of	 FAC-sorted	 neuronal	 cells	 derived	 from	 Tg(HuC:EGFP)as8	 and	 Tg(mnx1:GFP)ml2	
neuronal	 transgenic	 reporter	 embryos	 uncovered	 substantial	 expression	 of	 flt1	 in	 the	
neuronal	 system.	 Expression	 in	 the	 nervous	 system	 is	 interesting	 since	 Mukouyama	 has	
noticed	 that	 the	 peripheral	 sensory	 nerves	 release	 VEGF-A,	 which	 may	 promote	
arteriogenesis	 via	 activation	 of	 NRP1	 and	 KDR;	 capillaries	 are	 “upgraded”	 and	 start	 to	
express	arterial	markers	like	ephrinb2	and	Nrp1.	
	
To	 understand	 the	 potential	 contribution	 of	 vascular	 Flt1	 and	 neuronal	 Flt1	 in	 vascular	
morphogenesis,	we	subsequently	generated	tissue-specific	flt1	mutants	and	constitutive	full-	
and	isoform-specific	mutants.	We	next	compared	the	vascular	and	neuronal	phenotypes	of	
the	 tissue-specific	 mutants	 with	 the	 phenotypes	 observed	 in	 the	 constitutive	 flt1	 mutant	
embryos	 (Wild,	 Klems	 et	 al.	 2017).	 Flt1	 full	 mutants	 developed	 severe	 vascular	
hyperbranching	 at	 the	 level	 of	 the	 neural	 tube,	 whereas	 the	 nervous	 system	 showed	 no	
obvious	 dysmorphogenesis.	 Neuron-specific	 deletion	 of	 flt1	 phenocopied	 the	 vascular	
hyperbranching	phenotype.	Interestingly,	ablation	of	vascular	flt1	did	not	affect	branching	of	
the	 trunk	 vasculature	 in	 zebrafish	 embryos.	Using	 a	 panel	 of	mutants	with	vegfaa	 gain	 of	
function	(GOF)	scenarios,	we	subsequently	showed	that	neurons	are	a	prominent	source	of	
Vegfaa,	a	potent	pro-angiogenic	cytokine.	Pten	mutants	and	vhl	mutants	showed	increased	
neuronal	 vegfaa	 and	 hyperbranching	 at	 the	 level	 of	 the	 neural	 tube,	 similar	 to	 the	 flt1	
mutants.	 Combining	 flt1	 mutants	 with	 vhl	 mutants	 resulted	 in	 even	 more	 pronounced	
excessive	branching	and	complex	branched	networks	at	the	spinal	cord	level.	Based	on	these	
observations	we	proposed	the	following	mechanism	of	action:	During	early	embryogenesis	
neurons	 produce	 sFlt1,	 which	 restricts	 angiogenesis	 at	 the	 neurovascular	 interface	 in	
response	 to	 neuron-derived	 Vegfaa.	 Neurons	 are	 a	 prominent	 source	 of	 Vegfaa	 at	 early	





vegfaa	mRNA	 levels	even	promotes	sprouting	 into	 the	neural	 tube.	We	could	 furthermore	
show	 that	 this	 mechanism	 determines	 the	 onset	 and	 extent	 of	 vascularization	 during	
development	of	the	nervous	system	in	wild	type	(WT)	embryos.	
	
Our	 observations	 were	 surprising	 in	 several	 ways.	 First	 of	 all,	 the	 tissue-specific	 mutants	






(Tintu	 et	 al.	 2009).	 The	 physiological	 relevance	 for	 neurons	 to	 produce	 sFlt1	 may	 be	 to	
protect	neighbouring	cells	from	exposure	to	toxic	Vegfaa	levels	and	uncoordinated	growth.		
Third,	we	found	that	 in	 loss	of	 flt1	mutants	or	gain	of	vegfaa	models	angiogenic	sprouting	
emanated	from	veins,	a	vascular	domain	with	comparatively	 low	flt1	expression.	Using	cell	





WT	 hosts,	 strongly	 suggest	 that	 vascular	 Flt1	 is	 redundant	 for	 sprout	 differentiation	 and	
guidance.	However,	TgBAC(flt1:YFP)hu4624	and	WISH	using	probes	selective	for	mflt1	or	sflt1	











far,	 to	 our	 knowledge,	 no	 studies	 are	 available	 showing	 the	 Flt1	 protein	 localization	 in	
developing	 vascular	 networks.	 Also	 the	 potential	 contribution	 of	 the	 concentration	 and	
distribution	of	the	Flt1	ligands	has	not	been	considered.	We	therefore	decided	to	reconsider	
the	current	concepts	on	the	role	of	vascular	Flt1,	using	an	unbiased	approach	by	employing	a	
combination	 of	 mutants,	 gain	 of	 function	 transgenics	 and	 knock-ins.	 We	 started	 with	
mapping	the	expression	of	flt1	at	the	levels	flt1	promoter	activity,	flt1	mRNA	expression	and	
Flt1	 protein	 distribution.	 For	 the	 latter,	 we	 generated	 novel	 flt1-HA	 tagged	 knock-in	
transgenic	 fish	 (TgTm(flt1_E3_HAHA)ka601),	 allowing	 for	 the	 first	 time	 evaluation	 of	 Flt1	




of	 collateral	 arteries	 critically	 determines	 the	 flow	 delivery	 to	 the	 compromised	 hypo-
perfused	regions.		In	this	context	we	present	a	model	how	arterial	Flt1	could	act	as	a	sink	for	









purpose	 we	 took	 advantage	 of	 the	 TgBAC(flt1:YFP)hu4624	 transgenic	 fish	 allowing	 in	 vivo	
visualization	of	 flt1	 promoter	 activity.	 From	early	 developmental	 stages	onward	we	 found	
that	 flt1	 was	 predominantly	 expressed	 in	 the	 arterial	 system;	 aorta	 and	 arterial	
intersegmental	vessels	readily	expressed	YFP,	the	PCV	lacked	flt1	expression.	It	is	established	
that	formation	of	the	aISVs	is	driven	by	Vegfaa	and	depends	on	Notch	signalling	(Gore	et	al.	
2012).	 In	 the	 current	 angiogenesis	 models,	 it	 is	 postulated	 that	 Vegfaa	 activates	 Kdrl	







and	 pepper”	 pattern	 for	 flt1	 expression/promoter	 activity.	 Careful	 examination	 of	




However,	 promoter	 activity	 and	 mRNA	 expression	 do	 not	 reveal	 whether	 the	 protein	 is	




this	dual	approach	we	should	be	able	 to	obtain	sufficient	 resolution	 to	detect	Flt1	protein	
expression	by	endothelial	cells	and	the	distribution	of	sFlt1	protein	around	growing	vessels.			
	
In	 order	 to	 analyse	 the	 endogenous	 Flt1	 protein	 distribution,	 a	 CRISPR/Cas9-mediated	
knock-in	of	the	HAHA	tag	into	the	zebrafish	flt1	gene	was	performed.	By	parallel	injection	of	
an	sgRNA	targeting	Exon	3	of	flt1	(sgRNAfltE3),	Cas9	mRNA	and	an	oligonucleotide	composed	
of	 the	 HAHA	 tag	 flanked	 by	 left	 and	 right	 flt1	 homology	 arms,	 the	 knock-in	 line	
TgTm(flt1_E3_HAHA)ka610	was	generated.	This	line	has	a	HAHA	knock-in	in	exon	3,	coding	for	
the	extracellular	Ig1	domain	(Figure	8m),	thus	both	sFlt1	and	mFlt1	are	tagged.	Surprisingly,	
when	 an	 anti-HA	 immunohistochemistry	 (IHC)	was	 performed	 in	TgTm(flt1_E3_HAHA)ka610	
embryos,	Flt1	protein	was	found	on	membranes	and	in	the	immediate	vicinity	of	the	aISVs	at	
32hpf	 (Figure	 8n,o).	 In	 addition,	 Flt1	 protein	 was	 found	 close	 to	 EC	 nuclei	 in	 aISVs.	 This	




ISV-specific	 flt1enh	 promoter	 (Bussmann	 et	 al.	 2010).	 These	 fish	were	 embryonically	 lethal	
because	the	growth	of	ISVs	was	prevented	(data	not	shown),	suggesting	that	the	function	of	






In	 line	with	 the	knock-in	approach,	 IHC	with	an	anti-HA	antibody	 in	 the	double	 transgenic	
line	Tg(kdrl:hsa.HRAS-mcherry)s916;Tg(flt1enh:sflt1_	Δ7-HAHA)ka611	revealed	that	sFlt1	protein	
was	localized	directly	on	the	primary	aISVs	at	30hpf,	and	no	diffusion	and	gradient	of	sFlt1	
could	 be	 observed	 (Figure	 8g-i).	 Green	 dots	 dispersed	 along	 the	 complete	 trunk	 were	
unspecific	 background,	 as	 these	 were	 also	 found	 in	 control	 WT	 embryos	 (Figure	 8h,k,	
rectangular	 inlets).	 At	 48hpf	 sFlt1	 protein	 was	 still	 in	 the	 immediate	 vicinity	 of	 the	 aISVs	
(Figure	8j-l,	arrowheads	 in	k	 indicate	aISVs).	 In	 line	with	 the	 flt1	expression	data	on	vISVs,	
which	 had	 been	 remodelled	 from	 aISVs,	 there	 was	 sFlt1	 protein	 detectable	 in	 the	 dorsal	




Taken	 together,	 in	 TgBAC(flt1:YFP)hu4624	 we	 found	 no	 “salt	 and	 pepper”	 flt1	 expression	
pattern;	instead,	we	found	flt1	expression	throughout	the	developing	sprout	in	tip,	stalk	and	
base	 cells.	 In	 the	 TgTm(flt1_E3_HAHA)ka610	 transgenic	 fish	 we	 found	 a	 similar	 pattern:	 Flt1	
protein	was	expressed	 throughout	 the	developing	arterial	 sprout	and	 in	 the	axial	 arteries.	
Except	 for	the	remodelled	artery-derived	venous	endothelial	cells,	 the	venous	domain	was	
devoid	of	Flt1	protein.	In	the	Tg(flt1enh:sflt1_	Δ7-HAHA)ka611	we	found	that	the	majority	of	
the	 Flt1	 protein	 remains	 at	 or	 closely	 around	 the	 endothelial	 cell	 membrane	 and,	
surprisingly,	in	the	nucleus.	These	data	suggest	that	all	arterial	endothelial	cells	in	sprouting	









(yellow	 arrows).	 (d)	 Flt1	 expression	 is	 also	 found	 in	 the	 anastomosing	 tip	 cells	 in	 DLAV	 formation	 (red	
arrowheads).	(e)	At	48hpf,	flt1	is	expressed	in	the	complete	aISVs,	the	DA	and	in	the	DLAV.	(f)	Depiction	of	the	
strategy	 for	 generating	 the	 transgenic	 line	 Tg(flt1enh:sflt1__	Δ7-HAHA)ka611.	 (g-l)	 Representative	 confocal	
images	 of	 an	 IHC	 staining	 with	 an	 anti-HA	 antibody	 in	 the	 double	 transgenic	 line	 Tg(kdrl:hsa.HRAS-
mcherry)s916;Tg(flt1enh:sflt1_	Δ7-HAHA)	ka611.	For	control	embryos	(rectangular	inlets	in	h,k)	IHC	was	performed	
in	WT	embryos	in	parallel	to	the	Tg(flt1enh:sflt1__	Δ7-HAHA)	and	they	were	imaged	with	the	same	microscope	
settings	 as	 the	 transgenic	 embryos	 in	 g-l.	 Note	 that	 sFlt1	 is	 not	 diffusing	 away	 from	 the	 ISV.	 (i,l)	 Note	 that	
merged	images	reveal	that	sFlt1	is	distributed	along	the	complete	ISVs,	showing	that	sFlt1	is	not	diffusing	far	
away	from	the	ISVs.	In	the	DA	at	48hpf,	sFlt1	is	localized	in	the	dorsal	part.	(m)	Depiction	of	the	HAHA	knock-in	
in	 flt1	 exon	 3	 encoding	 the	 Ig1	 domain	 (TgTm(flt1_E3_HAHA)	 ka610).	 (n)	 IHC	 with	 an	 anti-HA	 antibody	 in	
TgTm(flt1_E3_HAHA)	ka610	 embryos	 at	 32hpf.	 Note	 that	 both	mFlt1	 and	 sFlt1	 are	 localized	 very	 close	 to	 the	
aISVs	over	the	whole	ISV	length.	Furthermore,	they	can	be	detected	in	the	dorsal	DA	close	to	the	hypochord.	
(o)	 Magnification	 of	 n	 as	 depicted	 by	 white	 rectangular	 inlet.	 Note	 that	 Flt1	 protein	 is	 accumulating	 in	 EC	











This	 leaves	 us	with	 the	 fundamental	 question:	What	 is	 then	 physiological	 the	 function	 of	
vascular	 Flt1	 in	 growing	 networks?	 Evidence	 is	 accumulating	 suggesting	 that	 Flt1-specific	
ligands	 like	 Plgf	 compete	 with	 Vegfa	 for	 binding	 at	 Flt1	 and	 thereby	 change	 Vegf	 bio-


















fluorescent	 motoneuronal	 reporter	 lines,	 Tg(nrp1a:GFP)js12	 and	 Tg(mnx1:GFP)ml2	 	 (Figure	
9p,q).	In	these	lines,	plgf	WISH	was	performed	at	24hpf	when	its	signal	peaked	(Figure	9f,i,l),	
followed	by	an	anti-GFP	staining	(Figure	9e,h,k)	to	overcome	possible	detection	 limitations	
by	 photo	 bleaching	 of	 the	 GFP	 during	 the	WISH	 procedure.	 Indeed,	 plgf	 colocalized	 with	
Results 
 40 









m	 from	 a	 dorsal	 view	 as	 outlined	 in	 o	 and	 p,	 respectively.	 (e,h,k)	 Confocal	 images	 of	 anti-GFP	 staining	 of	
Tg(nrp1a:GFP)js12	 and	 Tg(mnx1:GFP)ml2.	 The	 staining	 was	 performed	 after	 the	WISH.	 (f,i,l)	 Transmitted	 light	
images	of	plgf	WISH,	with	plgf	expression	in	dark	grey	as	indicated	by	black	arrows.	(g,j,m)	Merged	images	of	
motoneuron	 transgenic	 lines	 and	 plgf	 expression.	 Note	 that	 plgf-expressing	 cells	 colocalize	with	mnx1+	 and	
nrp1a+	 cells	 as	 marked	 by	 arrowheads.	 (p,q)	 Confocal	 images	 of	 Tg(nrp1a:GFP)js12	 and	 Tg(mnx1:GFP)ml2	 at	








reflected	 an	 endogenous	 decline	 of	 plgf	 expression,	 we	 took	 advantage	 of	 another	
technique	to	visualize	endogenous	gene	expression,	namely	bacterial	artificial	chromosome	
(BAC)	 transgenesis	 (Bussmann	&	Schulte-Merker	2011).	Therefore,	we	chose	 two	different	
BACs,	 which	 both	 contained	 the	 complete	 plgf	 gene	 as	 well	 as	 large	 5’	 and	 3’	 genomic	
regions	 (Figure	 10r).	 These	 large	 upstream	 and	 downstream	 regions	 were	 needed	 to	
maximise	 the	 likelihood	 that	 the	 BACs	 contained	 all	 elements	 regulating	 plgf	 gene	
expression.	 Via	 several	 recombineering	 steps	 the	 fluorescent	marker	mCitrine	was	 pasted	
directly	 behind	 the	 ATG	 start	 codon	 of	 plgf,	 and	 tol2	 sites	 were	 inserted	 into	 the	 BAC	
backbone.	Upon	injection	of	the	BACs	together	with	tol2	transposase	mRNA	into	embryos	at	
the	 one	 cell-stage,	 the	 endogenous	 plgf	 expression	 could	 be	 imaged	 in	 the	 developing	
embryos.		
At	 32hpf	plgf	 expression	was	 observed	 in	 the	 somata	 and	 axons	 of	 primary	motoneurons	




























When	we	 started	 to	 analyse	 the	 second	 Flt1-specific	 ligand	 vegfb,	 no	 studies	 on	 vegfb	 in	
zebrafish	 were	 available	 and	 the	 genomic	 annotations	 were	 rather	 poor.	 As	 two	 vegfb	
variants	 on	 different	 chromosomes	 are	 annotated	 in	 the	 genome	 browsers	 NCBI	 and	
ENSEMBL,	vegfba	 (NCBI	Gene	 ID:	101885552)	and	vegfbb	 (NCBI	Gene	 ID:	100535766),	 in	a	





dimerization	 interface.	 As	 also	 the	 protein	 translated	 from	 vegfbb	 contains	 these	 three	
domains,	we	had	to	use	another	method	to	assess	which	of	these	forms	is	the	homologue	of	
the	 human	Vegfb.	 Therefore,	 we	 took	 advantage	 of	 the	 shared	 gene	 synteny	 analysis,	 in	
which	 the	 genomic	 surroundings	 of	 Vegfb	 in	 zebrafish	 and	 humans	 were	 scanned	 for	
common	genes.	Such	a	shared	synteny	analysis	revealed	that	both	the	human	Vegfb	and	the	
zebrafish	vegfba	share	a	gene	in	their	upstream	region.	No	shared	gene	synteny	was	found	
between	 zebrafish	 vegfbb	 and	 human	 Vegfb.	 Given	 these	 computational	 analyses,	 we	
decided	to	focus	on	vegfba	for	further	analysis,	hereafter	called	vegfb	for	simplicity.		
	
In	 a	 next	 step,	 we	 analysed	 the	 expression	 patterns	 of	 vegfb	 during	 embryogenesis.	 To	
discriminate	between	the	two	isoforms,	we	designed	different	RNA	antisense	probes	(Figure	


















that	 in	 trunk	vegfb	 is	neither	expressed	 in	 the	neuronal	nor	 in	 the	vascular	 system.	 (c)	Depiction	of	 the	 two	
vegfb	isoforms	and	RNA	probe	localization.	The	first	3	exons	and	a	large	part	of	exon	4	are	identical	in	the	two	
isoforms.	Due	to	alternative	splicing	isoform	1	is	composed	of	8	and	isoform	2	only	of	5	exons.	RNA	probes	1	











tree	 in	 the	 trunk.	 Therefore,	 we	 performed	 a	 dynamic	 analysis	 of	 the	 ISV	 development	
during	 the	 first	 days	 of	 development.	 Time	 lapse	 confocal	 images	 of	 flt1-/-	 full	 mutants	
(flt1ka601)	 lacking	 both	mflt1	 as	well	 as	 sflt1	were	 carried	 out	 in	 the	 vascular	 reporter	 line	
Tg(kdrl:hsa.HRAS-mcherry)s916	 from	 25	 to	 73hpf	 (Figure	 12).	 At	 25hpf,	 during	 primary	
sprouting	 and	 before	 forming	 anastomoses	 with	 their	 neighbours,	 the	 diameter	 of	 the	
ventral	part	of	the	growing	sprout	was	clearly	enlarged	in	flt1-/-	mutant	compared	with	WT	
ISVs	(Figure	12a,b).	After	the	completion	of	anastomosis	formation	and	the	onset	of	blood	
flow	 at	 38hpf	 the	 ISV	 diameter	 over	 the	 whole	 ISV	 length	 was	 increased	 in	 the	mutants	
(Figure	12c,d).	At	73hpf	no	difference	in	ISV	diameter	between	WT	and	flt1-/-	mutants	could	
be	observed	anymore.	To	assess	the	diameter	of	a	single	ISV,	the	diameter	was	measured	at	
seven	points	 along	 the	 ISV	 (Figure	12c)	 and	 the	average	was	 calculated	 (Figure	12c).	 Such	
quantification	 of	 ISVs	 in	 time	 lapse	 series	 corroborated	 the	 observations	 of	 a	 diameter	





(a-h)	 Still	 images	of	a	 confocal	 time	 lapse	of	 the	 transgenic	 line	Tg(kdrl:hsa.HRAS-mcherry)s916	with	 indicated	
time	points.	(a,b)	The	diameter	of	flt1-/-	(flt1ka601)	ISVs	is	enlarged	compared	with	WT	during	primary	sprouting,	











We	 found	 that	 the	 hypersprouting	 phenotype	 in	 flt1-/-	 was	 due	 to	 a	 gain	 of	 Vegfaa	
bioavailability	at	the	level	of	the	neural	tube	(Wild,	Klems	et	al.	2017).	To	determine	whether	
this	 was	 also	 the	 case	 for	 the	 diameter	 increase	 observed	 in	 flt1-/-	mutants,	 we	 analysed	
whether	 overexpressing	 vegfaa	 could	 phenocopy	 their	 diameter	 increase.	 This	
overexpression	 was	 supposed	 to	 be	 done	 in	 a	 tissue	 where	 vegfaa	 is	 endogenously	
expressed,	as	increased	Vegfaa	levels	in	flt1-/-	could	only	stem	from	a	tissue	where	Vegfaa	is	
in	place	anyway.	As	the	neuronal	gain	of	Vegfaa	due	to	loss	of	neuronal	flt1	was	responsible	
for	 another	 phenotype,	 namely	 venous	 hypersprouting	 at	 the	 neural	 tube	 at	 later	
developmental	 time	 point	 (Wild	 et	 al.	 2017),	 we	 precluded	 the	 spinal	 cord	 as	 source	 of	
vegfaa	 for	 the	 observed	 diameter	 phenotype	 in	 flt1-/-.	 As	 mentioned	 before,	 the	 other	
source	 of	 vegfaa	 in	 the	 early	 developing	 zebrafish	 embryo	 are	 the	 somites	 (Jensen	 et	 al.	
2015),	 thus	we	overexpressed	vegfaa	 under	 the	 skeletal	muscle-specific	 promoter	503unc	
(Berger	&	Currie	2013).	As	Vegfa165	is	the	important	isoform	in	mice	(Maes	et	al.	2002)	and	
because	vegfaa121	 as	well	as	 -165	both	possess	a	 similar	angiogenic	potential	 (Wild	et	al.	
2017),	we	focussed	on	vegfaa165	 for	GOF	experiments.	 In	order	to	track	the	expression	of	
vegfaa	with	 a	 fluorescent	 tag	without	 affecting	 the	protein	 functionality,	 the	 sequence	of	





30hpf	 the	 blood	 vessels	 were	 very	 disorganized,	 non-functional	 and	 resembled	 a	 tumour	
vasculature	 or	 hemangioma	 with	 uncontrolled	 EC	 proliferation	 (Figure	 13c,d).	 This	
phenotype	did	 not	 resemble	 the	 diameter	 increase	 observed	 in	 the	 flt1-/-	mutants	 (Figure	
12).	
Notably,	there	were	still	ISV-like	structures	recognizable	in	vegfaa165cMC	embryos	and	their	
spacing	 was	 similar	 to	 WT	 (Figure	 13c,	 white	 asterisks).	 Therefore,	 somatic	 vegfaa	
overexpression	could	not	induce	additional	sprouts	from	the	axial	vessel.		
We	 speculated	 that	 the	 timing	 of	 the	 onset	 of	 vegfaa165	 expression	 in	 the	 somites	 was	
crucial	for	the	diameter	increase	and	we	decided	to	start	the	overexpression	at	a	time	point	




transcription	activator	protein,	under	a	 tissue-specific	promoter	of	 choice	can	activate	 the	
expression	of	upstream	activator	sequence	(UAS)-linked	genes.	By	fusing	Gal4	to	a	variant	of	




added	 endoxifen	 at	 28hpf,	when	 the	 ISVs	 and	DLAV	were	 already	 developed,	 and	 started	
time	lapse	imaging	at	32hpf	(Figure	13a).	At	32hpf	the	expression	in	the	muscles	had	already	
commenced	 (Figure	 13g)	 and	 the	 ISV	 diameter	 was	 increased	 in	 vegfaa165iMC	 embryos	
compared	to	WT	(Figure	13e,f).	Over	time	the	vegfaa165	expression	levels	were	rising	and	
concomitantly	the	diameter	continued	to	further	augment	(Figure	13h-s).	Other	than	in	flt1-/-	
mutants	 the	 ISVs	enlargement	was	accompanied	by	a	progressive	disruption	of	 the	 vessel	
integrity	 (Figure	 13l,o,r,	 white	 arrowheads).	 Eventually,	 20	 hours	 after	 the	 expression	
induction	 the	 levels	 were	 that	 high	 that	 the	 ISVs	 in	 vegfaa165iMC	 adopted	 a	 similar	
disorganized	morphology	 (Figure	13u,v,	 red	arrowheads)	as	 in	vegfaa165iMC	 (Figure	13c,d).	








(a)	 Depiction	 of	 the	 different	 experimental	 procedures	 for	 muscle-specific	 vegfaa165	 GOF.	 For	 constitutive	
overexpression	 of	 GFP-p2A-vegfaa165	 in	 the	 somites	 under	 the	 muscle	 promoter	 503unc	 (vegfaacMC),	 the	
vegfaa165	expression	starts	with	the	promoter	activity	of	503unc,	 i.e.	before	20hpf,	and	embryos	are	imaged	
at	 30hpf.	 For	 inducible	 muscle	 cell-specific	 GFP-p2A-vegfaa165	 GOF	 (vegfaaiMC)	 two	 plasmids	 encoding	
503unc:gal4-ERT2	and	UAS:GFP-p2A-vegfaa165,	respectively,	are	injected	at	the	one	cell-stage	and	expression	
is	 induced	at	28hpf	via	endoxifen	administration;	confocal	 imaging	is	started	4	hours	later.	(b)	ISVs	in	the	WT	
control.	 (c,d)	 Growth	 of	 ECs	 is	 highly	 uncoordinated	 in	 vegfaacMC	 embryos,	 resembling	 the	 non-functional	
vasculature	 of	 a	 tumour.	 Note	 that	 the	 discernible	 spacing	 between	 two	 ISV-like	 vessels,	 marked	 by	 white	
asterisks,	resembles	the	normal	distance	between	ISVs,	thus	no	additional	sprouts	from	the	axial	vessels	were	
induced	 by	 vegfaacMC.	 (e-v)	 Still	 images	 of	 a	 time	 lapse	 of	 WT	 and	 vegfaaiMC	 from	 32hpf,	 i.e.	 4h	 after	 the	
endoxifen	induction,	until	48hpf.	(e-g)	Note	that	GFP-p2A-vegfaa165	has	already	commenced	at	the	time	lapse	
starting	 point	 and	 that	 the	 ISV	 diameter	 is	 increased	 compared	 to	 WT.	 (h-v)	 With	 increasing	 GFP-p2A-
vegfaa165	 expression	 levels	 the	 ISV	 diameter	 is	 further	 growing.	 Note	 that	 ISV	 diameter	 augmentation	 is	
accompanied	by	progressive	disruption	of	the	vessel	integrity,	marked	by	white	arrowheads	in	l,o,r,	until	they	
are	 completely	 disintegrated	 at	 48hpf,	 indicated	 by	 red	 arrowheads	 in	 u,v.	 (w)	 Quantification	 of	 the	 ISV	














a	 gene	 delivery	 GOF	 scenario	 is	 way	more	 difficult,	 as	 the	 exact	 amount	 cannot	 be	 fine-
tuned.	We	assumed	that	a	dexterous	way	to	overcome	this	limitation	on	dosage	control	was	
to	take	advantage	of	the	endogenous	Vegfaa	“reservoir”,	which	is	the	Vegfaa	sequestered	by	
Flt1.	 A	 way	 to	 release	 Vegfaa	 from	 Flt1	 is	 the	 competitive	 binding	 of	 the	 Flt1-exclusive	
ligands	Plgf	or	Vegfb	to	Flt1.	Such	release	from	Flt1	by	competitive	binding	can	occur	if	the	
levels	 of	 Plgf	 and	 Vegfb	 are	much	 higher	 than	 the	 Vegfaa	 levels,	 a	 scenario	 that	may	 be	
accomplished	by	overexpressing	plgf	and	vegfb.	As	a	spatially	controlled	Vegfaa	 release	at	




(plgfcMC),	 plgf	 was	 cloned	 behind	 GFP,	 connected	 by	 the	 self-cleaving	 peptide	 p2A	 to	
preserve	 Plgf	 protein	 functionality,	 and	 the	 plasmid	 was	 injected	 together	 with	 tol2	
transposase	mRNA	 into	 zebrafish	 at	 the	 one	 cell-stage	 (Figure	 20a).	 Confocal	 time	 lapse	
imaging	of	the	blood	vessel	development	of	plgfcMC	in	the	Tg(kdrl:hsa.HRAS-mcherry)s916	line	
revealed	that	already	at	32hpf	there	was	a	remarkable	diameter	increase	compared	to	WT	
embryos,	 especially	 in	 the	 ventral	 part	 of	 the	 ISVs	 (Figure	 14a,b).	 At	 48hpf	 the	 diameter	
along	 the	 complete	 length	 of	 the	 ISVs	 was	 increased	 in	 plgfcMC	 embryos	 (Figure	 14c,d),	
similar	to	flt1-/-	embryos.	Remarkably,	quantitative	comparison	of	the	diameters	of	aISVs	and	
vISVs	 at	 48hpf	 revealed	 that	 particularly	 the	 arterial	 diameter	 was	 increased	 in	 plgfcMC	







having	 decreased,	 the	 arterial	 diameter	 was	 still	 significantly	 larger	 in	 plgfcMC	 embryos	





The	 complete	 time	 course	of	 the	diameter	 development	 in	plgfcMC	 versus	WT	 is	 shown	 in	
Figure	14j	 in	 intervals	of	3-4	hours,	 summarizing	 that	a	diameter	 increase	proceeded	until	











the	 ISV	 diameter	 of	 the	 ventral	 as	 well	 as	 the	 dorsal	 part	 of	 the	 ISVs	 in	 plgfcMC	 is	 remarkably	 increased,	
indicated	by	red	arrowheads.	(i)	Depiction	of	measurement	points	for	determining	the	average	diameter	of	one	
ISV.	(j)	Quantification	of	total	average	ISV	diameters,	 i.e.	without	compartmentalization	in	aISVs	and	vISVs,	 in	
plgfcMC	 and	 WT	 based	 on	 time	 lapse	 images	 from	 32hpf	 until	 74hpf	 every	 3h.	 Note	 that	 there	 is	 a	 highly	
increased	diameter	 in	plgfcMC	 compared	 to	WT	until	 45hpf,	 the	approximate	 time	point	 at	which	artery-vein	
remodelling	has	finished.	Subsequently,	the	vessel	diameter	is	decreasing	until	there	is	no	diameter	difference	
anymore	between	plgfcMC	and	WT	at	73hpf.	(k-m)	Specification	of	total	average	ISV	diameter	as	shown	in	j	into	
arterial	 vs.	 venous	diameter	 (aISV	and	vISV,	 respectively)	at	 the	 indicated	 time	points.	 (k)	At	48hpf	both	 the	
arterial	 and	 venous	 diameter	 are	 increased	 in	 plgfcMC	 compared	 to	 WT.	 Remarkably,	 upon	 plgf	 GOF	 the	
enlargement	of	aISV	diameter	is	significantly	higher	than	that	of	vISVs.	(l)	At	62hpf	the	diameter	difference	of	
aISVs	between	plgfcMC	and	WT	has	decreased	but	 is	still	 significant.	However,	 the	vISV	diameter	difference	 is	
not	significant	anymore.	(m)	At	74hpf	also	aISVs	of	plgfcMC	embryos	are	not	significantly	 larger	anymore	than	










ki8751	 was	 applied	 to	 plgfcMC	 embryos	 at	 32hpf,	 they	 were	 incubated	 for	 1.5	 days	 and	
subsequently	 imaged	 (Figure	15a).	 Blockade	of	R2	 signalling	 reduced	 the	aISV	diameter	 in	
WT	 (Figure	 15b,d,n)	 as	well	 as	 in	plgfcMC	 embryos	 (Figure	 15c,e,n).	However,	 the	 RI	 of	 R2	
inhibitor-treated	plgfcMC	aISVs	normalized	to	WT	aISVs	was	still	1.25	(Figure	15o),	thus	Kdrl	





as	 for	 R2	 blockade	 (Figure	 15a).	 However,	 as	 PI3K	 inhibition	 promotes	 arterial	 and	 blocks	






pharmacological	 PI3K	 blockade	 could	 completely	 rescue	 the	 outward	 remodelling	
phenotype,	even	to	lower	levels	than	in	WT	aISVs	(Figure	15k,m,r,s).		










by	 white	 dotted	 rectangles.	 (b,c,f,g,j,k)	 DMSO-treated	 controls.	 (d,e)	 aISVs	 of	 embryos	 treated	 with	 R2	
inhibitor.	Note	that	aISV	diameter	in	both	WT	and	plgfcMC	is	decreased	after	R2	blockade	compared	to	DMSO	
controls.	 (h,i)	 vISVs	 of	 embryos	 treated	 with	 R2	 inhibitor.	 Note	 that	 no	 difference	 in	 vISV	 diameter	 can	 be	
observed	compared	to	DMSO	controls	 in	 f,g.	 (l,m)	aISVs	of	PI3K	 inhibitor-treated.	Note	that	aISV	diameter	 is	
decreased	 in	 both	 genotypes	 compared	 to	DMSO	 controls	 in	 j,k.	 As	 AV	 remodelling	was	 impaired,	 no	 vISVs	
were	present	in	these	embryos.	(n,p,r)	Quantification	of	the	vessel	diameter	as	depicted	in	Figure	14i.	(o,q,s)	
Depiction	of	the	RIs	based	on	the	measurements	in	n,p,q	and	normalized	to	the	diameter	of	DMSO-treated	WT	
aISVs	or	 vISVs	 as	 indicated.	 (n,o)	 R2	 inhibition	 results	 in	 a	 decreased	 aISV	diameter	 in	 both	plgfcMC	 and	WT.	
Note	that	R2	blockade	cannot	completely	rescue	plgfcMC	aISV	diameter	to	WT	level.	(p,q)	R2	blockade	does	not	
significantly	 affect	 the	 vein	 diameter.	 (p)	 Inhibition	 of	 PI3K	 completely	 rescues	 the	 diameter	 in	 plgfcMC.	 R2,	





After	having	 found	 that	Kdrl	 signalling	and	 the	downstream	signalling	molecule	PI3K	were	













(a,b)	 ERK1/2,	 phospho-ERK1/2	 (pERK1/2),	 Akt,	 phospho-Akt	 (pAkt)	 Western	 blots	 of	 plgfcMC	 (pink)	 and	 WT	
(green)	at	indicated	time	points.	Numbers	indicate	biological	replicates.	(c)	(pERK1/2)/ERK	ratio	is	not	different	




Endothelial	 tip	 cell	 activation	 by	 VEGF-A	 –	 KDR	 signalling	 is	 associated	 with	 filopodia	
extensions	(Gerhardt	et	al.	2003).	Thus,	we	analysed	whether	the	increased	Kdrl	signalling	in	
plgfcMC	 embryos	 also	 induced	 a	 change	 in	 the	 EC	 architecture	 with	 respect	 to	 filopodia.	
Indeed,	at	32hpf	the	primary	aISVs	in	plgfcMC	embryos	extended	significantly	more	filopodia	
with	a	length	of	more	than	8µm	along	the	complete	ISVs	compared	with	WT	embryos	(Figure	
17a,b,i).	 At	 52hpf	 especially	 the	 aISVs	 of	 plgfcMC	 embryos	 contained	 more	 filopodia	
protrusions	with	a	length	of	more	than	4µm	than	WT	embryos	(Figure	17c,d,j).	Also	the	ECs	
in	 the	 DLAV,	which	 is	 formed	 by	 anastomoses	 of	 primary	 aISVs,	 displayed	more	 filopodia	
protrusion	longer	than	4µm	in	plgfcMC	than	in	WT		(Figure	17g,h,k).	








(a-h)	 Representative	 confocal	 images	 of	 the	 blood	 vessel	 filopodia	 of	 WT	 and	 plgfcMC.	 (a,c,e,g)	 In	 WT	 few	
filopodia	are	apparent	on	the	ISVs	at	32	and	52hpf	and	at	the	DLAV	at	52hpf.	 (b,d,f,h)	 In	contrast,	the	blood	
vessels	 of	 plgfcMC	 are	 covered	 with	 numerous	 filopodia	 at	 both	 time	 points,	 many	 of	 them	 having	 a	
considerable	 length.	 (i-k)	 Quantification	 of	 filopodia	 as	 outlined	 in	 (l).	 (i)	 Measurement	 of	 filopodia	 with	 a	
length	of	≥8µm	at	32hpf	reveals	a	significantly	higher	filopodia	number	on	plgfcMC	than	WT	ISVs.	(j,k)	At	52hpf	
significantly	more	filopodia	≥4µm	are	present	on	the	ISVs	and	the	DLAV	of	plgfcMCv	compared	to	WT.	Note	that	
in	plgfcMC	especially	 the	aISVs	are	coated	with	 filopodia.	Quantification	 in	 (i-k),	mean	±	 s.e.m;	 t-test;	 (i)	n=10	















not	 associated	 with	 an	 increased	 macrophage	 infiltration,	 as	 the	 macrophages	 in	 the	





(a-d)	Representative	confocal	 images	of	EC	nuclei	 in	 ISVs	 in	Tg(fli1a:nGFP)y1	 in	WT	and	plgfcMC.	 (a,b)	Primary	
arterial	 sprouting.	Note	 that	plgfcMC	 sprouts	 contain	more	ECs.	 (c,d)	plgfcMC	aISVs	at	32hpf	 contain	more	ECs	
over	 the	 whole	 length	 of	 the	 ISV.	 (e,f)	 Representative	 confocal	 images	 of	macrophages	 in	 the	 trunk	 in	 the	
Tg(mpeg1:GAL4-VP16)gl24;Tg(UAS:Kaede)s1999t	transgenic	line.	Note	that	the	macrophage	distribution	in	plgfcMC	
embryos	 is	not	different	from	WT.	(g)	Quantification	of	EC	number	per	 ISV	as	shown	in	a,b.	Quantification	 in	




As	 the	 gain	 of	 Vegfaa	 bioavailability	 by	 loss	 of	 flt1	 induced	 venous	 hypersprouting	 at	 the	





ectopic	 sprouts	 had	 venous	 origin	 (Figure	 19g).	 These	 sprouts	 subsequently	 formed	
anastomoses	with	adjacent	ISVs	or	the	DLAV,	and	thereby	the	ectopic	vessel	network	around	
the	NT	 extended	 (Figure	 19b,d-f).	 Constitutive	 neuron	 cell-specific	 overexpression	 of	GFP-
p2A-plgf	under	the	pan-neuronal	promoter	Xla.Tubb	(plgfcNC)	could	similarly	induce	ectopic	
sprouting	at	the	NT	(Figure	19h,i).	










4dpf,	 as	 indicated	by	 arrowheads,	 and	new	ectopic	 sprout	 emerges	 from	vISVs,	 indicated	by	 asterisk.	 (d)	 At	
5dpf	 there	are	numerous	anastomoses	at	 the	 level	of	 the	NT	 in	plgfcMC.	 (e)	Quantification	of	ectopic	sprouts	
(still	 growing	 as	 well	 as	 already	 anastomosed	 with	 another	 vessel)	 in	 WT	 and	 plgfcMC	 at	 4	 and	 5dpf.	 (f)	
Classification	of	the	sprouts	of	plgfcMC	 in	g	according	to	whether	they	have	already	formed	anastomoses	or	 if	
they	are	still	unconnected.	(g)	Quantification	of	the	venous	vs.	arterial	origin	of	ectopic	sprouts	in	plgfcMC.	For	
this	 analysis	 the	 unconnected	 sprouts	 at	 4dpf	 (h,	 left)	 were	 analysed.	 	 (j,k)	 Similar	 to	 muscle-specific	
overexpression	as	in	b,d	also	constitutive	neuronal	cell-specific	overexpression	of	GFP-p2A-plgf	under	the	nbt	





As	 plgfcMC	 caused	 a	 gain	 of	 Vegfaa	 bioavailability	 and	 Vegfaa	 is	 implicated	 in	 arterial	
differentiation	 (Dela	 Paz	 &	 D’Amore	 2009),	 we	 next	 checked	 whether	 the	 distribution	 of	
arteries	and	veins	was	affected	in	plgfcMC	embryos.	Therefore,	blood	vessels	were	analysed	
in	 a	Tg(flt1enh:dTomato)hu5333;Tg(flt4:mCitrine)hu7135	 double	 transgenic	 reporter	 line	 at	 4dpf	
with	 aISVs	 completely	 in	 red	 and	 veins	 having	 a	 ventral	 part	 exclusively	 in	 green	 (Figure	
20d,e).	However,	quantification	of	aISV	and	vISV	distribution	revealed	that	AV	differentiation	
was	regular	in	plgfcMC	embryos	(Figure	20b,c).	












plgf,	 tagged	via	p2A	 to	GFP,	under	 the	unc	promoter	 is	 injected	 together	with	 tol2	 transposase	mRNA.	 (b-e)	
Analysis	 of	 the	 artery-vein	 distribution	 in	 plgfcMC	 versus	 WT	 at	 4dpf.	 (b)	 Schematic	 depiction	 of	 the	 vessel	
identities	of	6	ISVs	above	the	yolk	sac	elongation	in	3	representative	embryos	per	group.	(c)	Quantification	of	
aISVs	and	vISVs	 in	WT	and	plgfcMC.	Note	 that	 there	 is	no	 significant	difference	between	 the	genotypes.	 (d,e)	
Confocal	images	of	the	blood	vessels	of	WT	and	plgfcMC	at	4dpf	with	indicated	vessel	identities.	(f)	Heart	rate	in	
plgfcMC	and	WT	embryos	at	32	and	48hpf.	Note	that	at	32hpf	no	significant	difference	exists	between	the	two	
genotypes,	 whereas	 at	 48hpf	 the	 heart	 rate	 increases	 in	 plgfcMC	 by	 the	 factor	 1.14.	 (g,h)	 Transmitted	 light	
images	of	WT	and	plgfcMC.	Note	that	plgfcMC	emryos	do	not	show	any	morphologic	malformations	or	oedema.	
(j)	Quantification	of	the	body	axis	length	of	WT	and	plgfcMC.	Length	measurements	were	performed	with	ImageJ	








To	 further	 substantiate	 that	 the	diameter	 increase	 in	 flt1-/-	 embryos	was	 due	 to	 a	 gain	 of	
Vegfaa,	we	constitutively	overexpressed	also	the	other	Flt1-specific	 ligand	vegfb	 in	skeletal	
muscles	(vegfbcMC)	with	the	same	approach	used	for	plgfcMC	(Figure	20a).	
Blood	 vessels	 of	 vegfbcMC	 embryos	 were	 dynamically	 imaged	 in	 the	 Tg(kdrl:hsa-HRAS-
mCherry)s916	 reporter	 line	from	31	to	74hpf.	Remarkably,	also	 in	vegfbcMC	the	 ISV	diameter	
was	 clearly	 enlarged	 compared	 to	 WT.	 Shortly	 after	 anastomosis	 formation,	 at	 31hpf,	
primarily	 the	 ventral	 part	 of	 the	 ISVs	were	 enlarged	 	 (Figure	 21a,b)	 in	 line	with	plgf	 GOF	
(Figure	14b)	and	flt1	LOF	(Figure	12b).	Later,	the	diameter	over	the	whole	range	of	the	ISVs	
was	 increased	 in	 vegfbcMC	 (Figure	 21d,e).	 Consistently	 with	 plgfcMC	 and	 flt1	 LOF,	 also	 in	




from	 Flt1	 and	 increased	 Kdrl	 signalling	 induced	 arteriolar	 outward	 remodelling	 in	 a	




put	 the	 ECs	 into	 an	 activated	 state,	 manifested	 by	 filopodia	 protrusions,	 and	 resulted	 in	
higher	EC	numbers	in	ISVs.	Remarkably,	plgfcMC	and	vegfbcMC	both	induced	a	higher	arterial	





	(a-f)	 Representative	 still	 images	 of	 confocal	 time	 lapse	 movies	 from	 31	 to	 74hpf	 of	 the	 reporter	 line	





vegfbcMC	 extend	many	 long	 filopodia.	 (c,d)	 At	 41hpf	 both	 ventral	 as	 well	 as	 dorsal	 parts	 if	 ISVs	 in	 vegfbcMC	
exhibit	an	 increased	diameter	as	denoted	again	by	 red	arrowheads.	 (e,f)	 Later	 in	development,	at	74hpf,	no	
difference	 in	vessel	diameter	between	WT	and	vegfbcMC	 is	noticeable.	 (g)	Quantification	of	 total	 average	 ISV	
diameters,	 i.e.	 without	 compartmentalization	 in	 aISVs	 and	 vISVs,	 in	 vegfbcMC	 and	 WT	 based	 on	 time	 lapse	
images.	 Individual	 average	 ISV	diameters	were	based	on	7	measurement	points	 as	 indicated	 in	 a.	Note	 that	
there	 is	a	highly	 increased	diameter	 in	vegfbcMC	compared	 to	WT	until	45hpf,	 the	approximate	 time	point	at	
which	 artery-vein	 remodelling	 has	 finished.	 Subsequently,	 the	 vessel	 diameter	 is	 decreasing	 until	 there	 is	
almost	 no	 diameter	 difference	 anymore	 between	 vegfbcMC	 and	 WT.	 (h)	 Comparison	 of	 the	 primary	 artery	













using	 CHOPCHOP	 in	 a	 way	 that	 no	 off-targets	 with	 0,1	 or	 2	 mismatches	 existed	 in	 the	
zebrafish	genome.	By	 screening	 for	 founder	animals,	a	mutant	with	a	10nt	deletion	allele,	
which	has	the	official	designation	plgfka609,	was	chosen	for	establishing	a	homozygous	plgf-/-	
line	(Figure	22c,d).	The	frameshift	in	these	mutants	(Figure	22ab)	causes	the	translation	of	a	


















We	 analysed	 the	 blood	 vessel	 development	 in	 plgf-/-	 mutants	 in	 the	 transgenic	 line	
Tg(kdrl:EGFP)s843.	 Primary	 ISVs	 sprouting	 and	 anastomosis	 formation	 as	well	 as	 secondary	














each	 image	as	outlined	by	dotted	 rectangular	boxes.	 (a,b)	Primary	sprouting	of	 ISVs	 (white	arrowheads)	and	
anastomosis	 formation	giving	rise	to	the	DLAV	(white	asterisks)	 is	occurring	regularly	 in	plgf-/-.	However,	 ISVs	
are	remarkably	thinner	in	plgf-/-	mutants	compared	to	WT.	(c,d)	Secondary	venous	sprouting	(white	arrows)	is	
also	 normal	 in	 plgf-/-.	 Note	 that	 at	 48hpf	 ISVs	 are	 still	 thinner	 in	mutants	 compared	 to	WT.	 (e,f)	 Images	 of	
arteries	and	veins	at	3dpf,	when	artery-vein	remodeling	is	fully	completed.	Note	that	venous	diameter	in	plgf-/-	
resembles	 the	WT	vISV	diameter,	whereas	arteries	 in	plgf-/-	 are	 thinner	 than	 in	WT.	 (g)	Quantification	of	 ISV	
diameter	at	32	and	48hpf	without	discrimination	between	aISVs	and	vISVs.	 (h)	Quantification	of	arterial	and	
venous	diameter	in	WT	and	plgf-/-.	(i)	RI	of	plgf-/-	aISVs	at	3	dpf,	normalized	to	WT	aISV	diameter.	Quantification	
in	 (g,h,i),	mean	±	 s.e.m;(g,h)	 t-test;	 (g,	 32hpf)	n≥16	 ISVs	 from	3	embryos	per	 genotype;	 (g,	 48hpf)	 n≥40	 ISVs	




As	 loss	 of	 plgf	 presumably	 affected	 the	 Vegfaa	 levels	 available	 for	 Kdrl	 signalling,	 we	
determined	the	AV	distribution	and	morphological	development	of	plgf-/-	mutants	similar	to	
the	analysis	of	plgfcMC	embryos.	 The	AV	distribution	 (Figure	24a-d)	was	normal,	 and	plgf-/-	









aISVs	 and	 vISVs	 in	WT	 and	plgf-/-.	 Note	 that	 there	 is	 no	 significant	 difference	 between	 the	 genotypes.	 (c,d)	
Confocal	 images	 of	 the	 blood	 vessels	 of	 the	 transgenic	 line	 Tg(kdrl:GFP)s843	 of	 WT	 and	 plgf-/-	 at	 3dpf	 with	
indicated	 vessel	 identities.	 (e-f)	 Transmitted	 light	 images	 of	WT	 and	plgf-/-.	 Note	 that	plgf-/-	mutants	 do	 not	
show	any	morphological	malformations	or	oedema.	(g)	Quantification	of	the	body	axis	length	of	WT	and	plgf-/-.	
Length	 measurements	 were	 performed	 as	 illustrated	 in	 e,	 red	 dotted	 line.	 Note	 that	 no	 significant	 size	
differences	 between	 the	 2	 genotypes	 were	 determined	 at	 all	 indicated	 time	 points.	 Quantification	 in	 (b,g),	












brain	 and	 analysed	 the	 cerebral	 vasculature	 in	 plgf-/-	 embryos.	 At	 2dpf	 the	 hindbrain	
consisted	 of	 the	 ventrally	 located	 primordial	 hindbrain	 channel	 (PHBC)	 in	 WT	 and	 plgf-/-	
embryos	 (Figure	 25a,b).	 CtAs	 were	 sprouting	 normally	 from	 the	 PHBC	 in	 plgf-/-	 embryos	
(Figure	 25a,b,	 white	 arrows),	 and	 the	 number	 of	 ipsilateral	 fusion	 formations	 was	 not	
affected	 (Figure	 25a,b,	white	 arrowheads).	 Also	 the	metencephalic	 artery	 (MtA)	 and	mid-
cerebral	vein	(MCeV)	were	developing	normally	in	plgf-/-	embryos	(Figure	25a,b).		As	the	CtAs	
were	reported	to	develop	in	a	non-stereotypic	manner	(Ulrich	et	al.	2011),	the	comparison	
of	 the	 CtA	 architecture	 between	 two	 animals	 is	 difficult;	 thus,	 a	 conclusive	 statement	 on	
possible	deviations	 in	CtA	number	 in	plgf-/-	mutants	 is	not	possible.	Nevertheless,	all	main	







the	 rhombomere	 boundaries	 to	 invade	 the	 hindbrain	 and	 which	 are	 connected	 via	 ipsilateral	 CtA	 fusions,	
indicated	by	white	arrowheads.	Note	that	the	early	plgf-/-	vasculature	develops	normally.	 (c,d)	Dorsal	view	of	
the	complete	cerebral	vasculature	at	6	dpf,	rostral	side	to	the	top.	The	main	vessels	in	the	cerebral	vasculature	
of	plgf-/-	mutants	 are	present,	 as	 indicated.	White	 arrows	 indicate	CtAs.	Note	 that	CtA	 architecture	 is	 highly	










order	 to	 examine	 the	 role	 of	 plgf	 in	 flt1	 full	 mutants,	 we	 generated	 flt1-/-;plgf-/-	 double	
mutants	 (official	 designation	 flt1ka601/ka602;plgfka609/ka609).	 However,	 no	 difference	 could	 be	
observed	between	 the	double	mutants	 and	 the	 flt1-/-	mutants	with	 respect	 to	 the	 venous	
hypersprouting	 phenotype	 at	 the	 neural	 tube	 (Figure	 26c-e).	 An	 additional	 small	 but	
consistent	phenotype	in	flt1-/-;plgf-/-	double	mutants	at	the	 level	of	the	hypochord	was	the	





(a,b)	Whole-mount	 in	 situ	 hybridization	of	plgf	 antisense	RNA	probe.	Note	 that	plgf	 is	highly	upregulated	at	
30hpf	in	motoneurons	and	in	the	hypochord	in	flt1-/-	compared	to	WT.	(c-h)	Representative	confocal	images	of	
blood	 vessels	 at	 4.5dpf.	 (c,d,e)	 Position	 of	 the	 neural	 tube	 is	 outlined	 by	white	 dotted	 rectangle.	 Note	 that	
there	is	similar	ectopic	hypersprouting	at	the	level	of	the	NT	in	flt1-/-	and	plgf-/-;flt-/-.	(f-h)	Representative	images	
of	aISVs	as	delineated	with	red	dotted	rectangle	in	c.	Note	that	the	aISV	in	plgf-/-;flt-/-	has	2	connections	to	the	
DA,	 here	 referred	 to	 as	 AA-shunt.	 (i)	 Quantification	 of	 embryos	 with	 AA-connection.	 AA,	 artery-artery;	 DA,	







Some	 studies	 in	 mouse	 report	 that	 the	 PlGF	 –	 FLT1	 axis	 is	 important	 for	 macrophage	
migration	 (Dewerchin	 &	 Carmeliet	 2012).	 In	 order	 to	 substantiate	 the	 relevance	 of	 our	
findings	 on	 the	 function	 of	 Flt1	 and	 Plgf	 for	 studies	 in	 mouse	 or	 even	 in	 the	 clinic,	 we	




Then	we	analysed	 the	macrophage	distribution	 in	 the	 trunk	and	 tail	of	 flt1-/-	 and	plgf-/-	by	
WISH	 for	 l-plastin,	 a	 macrophage	 marker	 (Herbomel	 et	 al.	 1999).	 Macrophages	 were	
accumulating	around	the	aorta	and	the	hypochord	in	WT	embryos,	the	expression	areas	of	
flt1	 and	plgf,	 respectively.	 In	 loss	 of	 flt1	 and	plgf	 embryos	 the	 propensity	 of	macrophage	
gathering	in	that	area	was	lost,	and	macrophages	dispersed	over	the	complete	trunk	and	tail	









	(a-d)	 Imaging	 of	 macrophage	 distribution	 at	 2dpf	 via	 WISH	 of	 l-plastin	 RNA	 probe,	 a	 macrophage	 marker	
(plasmid	kindly	provided	by	P.	Herbomel).	Note	that	macrophage	number	in	the	dorsal	trunk	and	tail	above	the	
DA	 is	 increased	 in	 plgf-/-	 and	 flt1ka601	 compared	 to	 WT,	 as	 outlined	 in	 red.	 (e,f)	 Quantification	 of	 the	
macrophage	 number	 in	 the	 trunk	 and	 tail	 dorsal	 to	 the	 DA,	 framed	 in	 red	 in	 a-d.	 (g,h)	 Confocal	 images	 of	
Tg(mpeg1:GAL4-VP16)gl24;Tg(UAS-E1b:Kaede)s1999t,	displaying	macrophages	in	green	at	4dpf.	Note	that	in	plgf-/-,	
also	at	4dpf	more	macrophages	are	located	in	the	dorsal	part	of	the	DA	and	HC	when	compared	to	WT,	in	line	
with	WISH	 images	 in	a,b	at	2dpf.	 (i)	Plgf	binding	to	Flt1	 is	conserved	 in	zebrafish.	The	zebrafish	forms	of	Plgf	
and	sFlt1	were	tagged	with	myc	and	HAHA,	respectively	(zPlgf-myc,	zsFlt1-HAHA),	and	transfected	in	HeLa	cells.	
Note	 that	upon	anti-HA-pullldown	the	anti-myc	detected	protein	corresponds	 to	zPlgf-myc,	 indicating	a	Plgf-














direct	 vascular	 growth,	 for	 example	 sensory	nerves	 can	 release	Vegf	 and	direct	 growth	of	
blood	vessels	 in	the	embryonic	skin	(Mukouyama	et	al.	2002).	Certain	motor	neurons	have	





the	 zebrafish	 embryo.	 For	 this	 purpose	 we	 examined	 embryos	 devoid	 of	 blood	 vessels	





gain	 of	 function	 embryos	 and	 focussed	 on	 the	 motoneurons	 in	 conjunction	 with	 the	
developing	vasculature.	








lapse	 images	of	the	double	transgenic	 line	Tg(kdrl:GFP)s843;Tg(Xla.Tubb:DsRed)zf148		 in	order	
to	 understand	 the	 chronology	 and	 spatial	 arrangement	 of	 the	 emerging	 ISVs	 and	 CaPs	
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As	 a	 next	 step	 in	 analysing	 the	 function	 of	 Vegf	 ligands	 as	 angioneurins,	 we	 aimed	 at	
determining	whether	the	development	of	CaP	axons	occurred	independently	of	 ISVs	 in	the	





structure	 including	 the	 aorta	 and	 the	 posterior	 cardinal	 veins.	 As	 a	 consequence	 these	
mutants	also	lack	intersegmental	vessels	and	a	DLAV,	and	there	is	no	blood	flow	perfusion.	
At	 later	 stages,	 these	 mutants	 show	 slight	 compensation	 and	 some	 primitive	 endothelial	





candidates	 using	 CRISPR/Cas9,	 they	 finally	 could	 show	 that	 the	 bHLH-PAS	 transcription	
factor	npas4l	(Reischauer	et	al.	2016)	is	functionally	responsible.	
	
We	 observed	 that	 in	 cloche	 (npas4lm378)	mutants	 in	 the	 absence	 of	 trunk	 vasculature	 CaP	
axons	 exited	 the	 neural	 tube	 in	 a	 regular	 and	 stereotyped	 manner,	 comparable	 to	 WT	
controls.	 Furthermore,	 the	 growing	 lateral	 line	 nerve	 (LLN)	 was	 positioned	 at	 the	














loss	 of	 blood	 vessels	 is	 the	 direct	 cause	 of	 the	 neuronal	 phenotype,	 or	whether	 neuronal	




GOF	 scenarios.	 Reducing	 Vegf	 inhibits	 ISV	 formation,	whereas	 augmenting	 Vegf	 promotes	
ISV	 branching	 (Wild	 et	 al.	 2017)	 –	 thus	 providing	 two	 scenarios	 to	 investigate	 changes	 in	
axonal	patterning.	
Insufficient	 Vegf	 levels	 are	 implied	 in	 motoneuron	 degeneration	 in	 amyotrophic	 lateral	




transgenic	 line	 Tg(kdrl:GFP)s843;Tg(Xla.Tubb:DsRed)zf148	 	 and	 compared	 them	 with	 WT	
embryos.	Vegfaa-/-	mutants	 lack	 intersegmental	vessels;	axial	vessels	are	 formed	but	show	
defects	in	expression	of	AV	markers,	and	the	embryos	do	not	develop	proper	perfusion.	
	We	 found	 that	 the	 CaP	 axon	 exit	 from	 the	 NT	 into	 the	 periphery	 was	 not	 affected	 in				
vegfaa	 -/-	 mutants,	 and	 the	 trajectory	 of	 the	 LLN	 was	 normal	 (Figure	 28w-y,z).	 Also	 the	
ventral	trajectory	of	CaP	axons	as	well	as	the	formation	of	a	distal	bifurcation	was	intact.	At	
the	 micro-level,	 quantification	 of	 the	 CaP	 axon	 length	 revealed	 that	 they	 were	 slightly	
shorter	 when	 compared	 with	 WT	 embryos.	 However,	 it	 needs	 to	 be	 emphasized	 that		
vegfaa-/-	mutants	 are	 slightly	dysmorphogenic	due	 to	 lack	of	 perfusion	and	 ISVs,	 and	 care	
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should	 be	 taken	 in	 interpretation	 of	 small	 phenotype.	 We	 conclude	 that,	 similar	 to	 the	
observations	 in	 cloche	 mutants,	 the	 global	 patterning	 of	 motoneurons	 was	 unaffected	 in	
vegfaa-/-	 mutant	 embryos	 lacking	 an	 appropriate	 trunk	 vasculature.	 At	 the	 micro-level,	






(a-o)	 Still	 images	of	 a	 time	 lapse	 confocal	movie	of	 the	emerging	motoneuron	axons	and	 ISVs	 in	 the	double	
transgenic	 line	 Tg(kdrl:GFP)s843;Tg(Xla.Tubb:DsRed)zf148.	 (d-f)	 The	 first	 contact	 between	 the	 dorsally	 growing	
vessels	and	the	NT	occurs	at	25.7hpf,	indicated	by	white	arrowheads.	(g-i)	At	approximately	32hpf	the	ventrally	




points.	 (p)	 High-magnification	 images	 of	 the	 axonal	 growth	 cone	 and	 the	 endothelial	 tip	 cell	 as	 outlined	 by	
white	dotted	rectangles	in	h	and	d,	respectively.	Both	consist	of	numerous	filopodia	extensions,	as	indicated	by	
red	 arrowheads.	 (t-v)	 Development	 of	 CaP	 axon	 extensions	 in	 the	 absence	 of	 blood	 vessels.	Npas4lm378/m378	
(also	known	as	clom378/m378)	mutants	are	lacking	a	functional	vasculature,	but	CaP	motoneurons	can	still	extend	
normally	 into	 the	 ventral	 direction	 and	make	distal	 bifurcations.	 In	 green,	 somite-derived	ECs.	 (w-y)	Vegfa-/-	
mutants	have	no	 ISVs.	Note	 that	also	 in	 the	absence	of	 ISVs	CaP	axons	 can	grow	ventrally	and	bifurcate.	 (z)	
Quantification	of	the	distance	between	two	CaP	exit	points	and	length	between	CaP	exit	point	and	bifurcation,	
indicated	 by	 white	 and	 yellow	 lines	 in	 q,	 respectively.	 Note	 that	 outgrowth	 and	 length	 of	 the	motoneuron	
axons	is	not	affected	per	se	by	the	absence	of	blood	vessels	in	npas4lm378/m378,	but	loss	of	vegfaa	affects	the	CaP	










plgf	 and	 vegfb,	 and	 in	 motorneurons,	 plgf	 production	 occurs	 concomitantly	 with	 the	
guidance	receptor	and	Vegf	co-receptor	nrp1a.		
	



















(a-f)	 Representative	 confocal	 images	 of	 plgf	 and	 vegfb	 GOF	 embryos	 in	 the	 pan-neuronal	 reporter	 line	
Tg(Xla.Tubb:DsRed)zf148.	White	asterisks,	CaP	exit	points;	white	arrowheads,	CaP	bifurcation.	(a,b)	Primary	CaPs	
develop	normally	 in	plgfcMC.	 (c,d)	Also	the	LLN	and	secondary	CaP-like	motoneurons	(here	also	referred	to	as	
CaPs)	 display	proper	 axonal	 patterning	 in	 plgfcMC.	 (e,f)	Ubiquitous	vegfb	GOF	 (vegfbubi)	 by	 injecting	100ng/µl	
vegfb	mRNA	does	not	affect	 the	axonal	patterning.	 (g)	 Illustration	of	CaP	axon	 length	measurement	 (yellow)	




per	 genotype	 and	 time	 point;	 (j)	 n=12	 CaP	 exit	 point	 distances	 from	 4	 embryos	 per	 genotype;(k)	 n≥13	 CaP	




As	 we	 had	 detected	 plgf	 expression	 in	 motoneurons	 (Figure	 9,Figure	 10),	 we	 decided	 to	
further	analyse	its	potential	endogenous	role	in	motoneuronal	patterning.	Analysis	of	plgf-/-	
mutants	 in	 the	 pan-neuronal	 reporter	 line	 Tg(Xla.Tubb:DsRed)zf148	 revealed	 no	 deviations	
with	 respect	 to	CaP	exit	point,	CaP	axon	 length	and	bifurcation	at	2dpf	 (Figure	30a,b,g,h).	
Also	 the	 extension	 of	 the	 neuronal	 network	 by	 CaP	 axon	 side	 branches	 at	 3dpf	 occurred	
regularly	 in	plgf-/-	mutants	 (Figure	 30c,d,	 yellow	 asterisks).	 Analysis	 of	 dorsal	 root	 ganglia,	
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which	 contain	 the	 sensory	 neuron	 somata,	 and	 Rohon-Beard	 neurons	 in	 the	








(a-d)	 Representative	 confocal	 images	 of	 the	 neuronal	 zebrafish	 trunk	 of	WT	 and	plgf-/-	 embryos	 in	 the	 pan-
neuronal	 reporter	 line	 Tg(Xla.Tubb:DsRed)zf148.	 White	 asterisks,	 CaP	 exit	 point;	 white	 arrowheads,	 CaP	
bifurcation.	(a,b)	The	outgrowth	of	the	CaP	axons	(yellow	arrowheads),	the	CaP	bifurcation	(white	arrowheads)	
and	 the	 LLN	 growth	 are	 normal	 in	plgf-/-	mutants.	 (c,d)	 At	 3dpf	 proper	motoneuronal	 network	 extension	by	
axonal	arborization	(yellow	asterisks)	is	taking	place	in	plgf-/-	embryos.	(e,f)	The	RB	sensory	neurons	as	well	as	
the	 DRG,	 which	 contain	 sensory	 neuron	 somata,	 develop	 normally	 in	 plgf-/-	 mutants	 as	 visualized	 by	 the								







Some	 nerves	 and	 vessels	 are	 running	 directly	 in	 parallel.	 We	 determined	 whether	 this	
patterning	was	affected	in	plgf-/-	mutants	at	4dpf.	
The	 parallel	 trajectories	 of	 the	 costal	 arteries	 (CAs)	 and	 the	 dorsal	 extensions	 of	 the	 CaP	
bifurcation	were	not	disturbed	in	plgf-/-	mutants	(Figure	31a,b).	Also	the	parachordal	vessel	












(arrowhead)	 is	 ventrally	 aligned	with	 the	DA	 (asterisk)	 in	 both	 genotypes.	 (e,f)	 LLN	 and	 PAV	 have	 a	 parallel	
trajectory	in	plgf-/-	and	WT	embryos.	(g,h)	ISVs	are	in	close	contact	with	the	NT.	Representative	images	of	n>10	
















Adaption	 of	 the	 arteriolar	 tree	 to	 changes	 in	 blood	 flow	 is	 essential	 for	 satisfying	 the	
metabolic	demands	of	an	organism.	Such	adaption	can	be	achieved	either	by	the	formation	
of	new	blood	vessels	during	angiogenesis	or	by	the	adjustment	of	the	arterial	diameter.	The	
radial	 expansion	 or	 growth	 of	 arterioles	 is	 also	 called	 structural	 outward	 remodelling,	 as	
opposed	 to	 functional	 enlargement	 of	 arterioles	 involving	 active	 vasodilation	 by	 active	
relaxation	of	surrounding	smooth	muscle	cells.	In	ischemic	diseases,	opening	of	pre-existing	
bypass	collaterals	involves	flow-driven	structural	outward	remodelling,	and	this	process	was	
originally	 referred	 to	 as	 “arteriogenesis”	 by	 Wolfgang	 Schaper,	 one	 of	 the	 pioneers	 in	
collateral	 vessel	 research	 (Schaper	 &	 Ito	 1996).	 During	 subsequent	 years,	 it	 has	 been	
recognized	that	besides	recruitment	of	native	collaterals,	additional	collateral	networks	may	
also	 be	 derived	 from	 “upgrading”	 capillary	 network	 into	 small	 conductive	 arteriolar	
networks.	 This	 process,	 sometimes	 referred	 to	 as	de	 novo	 arteriogenesis	 (Cristofaro	 et	 al.	
2013)	 involves	 both	 outward	 remodelling	 and	 imprinting	 of	 artery	 identity	 in	 capillary	
endothelial	 cells.	Arteriogenesis	 is	 considered	an	 important	 therapeutic	 target	 for	 treating	
ischemic	 cardiovascular	 diseases,	 and	 several	 molecules	 have	 been	 suggested	 for	 this	
purpose	including	ThymosinB4	(Bongiovanni	et	al.	2015;	Hinkel	et	al.	2014)	and	VEGF.	VEGF	
is	 the	 key	 factor	 for	 vascular	 development	 in	 health	 and	 disease	 and	 it	 is	 implied	 in	
numerous	aspects	of	creating	functional	vascular	networks	 including	structural	aspects	 like	
vascular	 branching,	 vascular	 diameter,	 functional	 aspects	 like	 permeability	 but	 also	
molecular	aspects	including	arterial	identity	(Lawson	et	al.	2002;	Weis	&	Cheresh	2005;	Swift	
&	Weinstein	 2009;	 Koch	&	Claesson-Welsh	2012).	Given	 its	 potency,	VEGF	has	been	 for	 a	
long	time	in	the	centre	as	cytokine	of	choice	for	therapeutic	neovascularization	(Grundmann	
et	 al.	 2007).	 However,	 experimental	 and	 clinical	 studies	 showed	 that	 VEGF	 is	 indeed	 very	
potent	but	very	difficult	 to	deliver	 locally	 in	 the	 right	dosage.	Many	 trials	 showed	adverse	
side	 effects	 including	 formation	 of	 hemangiomas,	 hypotension	 and	 aberrant	 vascular	
remodelling,	 in	 line	with	 vessels	 being	 very	 sensitive	 to	 VEGF	 and	 high	 VEGF	 levels	 being	









to	 the	 arterial	 system.	As	 a	 consequence,	 Flt1	 binds	Vegfaa	 in	 close	proximity	 to	 arteries.	
Arteries	express	Vegf	receptors;	hence,	 the	Flt1	receptors	are	providing	a	Vegfaa	reservoir	
close	 to	 the	 signalling	 receptors	 (Figure	 32a).	 However,	 Vegfaa	 cannot	 participate	 in	
signalling	since	it	is	bound,	and	we	found	no	evidence	for	Flt1:Kdrl	heterodimers	in	signalling	
in	the	zebrafish	embryo.	Loss	of	flt1	increases	arterial	diameter,	suggesting	that	arterial	Flt1	
normally	 acts	 to	 restrict	 outward	 remodelling.	 To	 release	 Vegfaa	 from	 Flt1	 we	 took	
advantage	 of	 the	 Flt1-specific	 ligand	 Plgf	 (Figure	 32b).	 Overexpression	 of	 plgf	 in	 close	
proximity	to	the	developing	arterioles,	for	example	in	the	surrounding	skeletal	musculature	
(of	note:	 collaterals	 in	 the	hindlimb	of	mouse	and	human	are	also	 surrounded	by	 skeletal	
muscle),	 promote	 structural	 outward	 remodelling	 of	 arterioles	 –	 within	 24	 hours	 the	
arterioles	 double	 their	 size,	 hence,	 increased	 flow	 capacity	 by	 factor	 16.	 In	 venules,	 there	
was	 only	 a	 20%	 increase.	 Pharmacological	 and	 genetic	 interventions	 showed	 that	 this	





We	 propose	 that	 arterial	 Flt1	 acts	 as	 a	 reservoir	 for	 Vegfaa	 in	 a	 local	 manner	 in	 close	





















10-fold	 higher	 affinity	 for	 VEGF	 than	 KDR,	 and	 hence,	 Flt1	 is	 considered	 to	 act	 as	 VEGF	
scavenging	receptor,	limiting	VEGF	bioavailability	and	signalling	through	KDR.	Flt1	is	spliced	
in	 two	 isoforms,	 the	membrane-bound	 form	 containing	 an	 intracellular	 signalling	 domain	
and	 a	 soluble	 form,	 sFlt1.	 At	 present	 it	 is	 believed	 that	 Flt1,	 regardless	 of	 the	 isoform,	 is	
produced	 in	 the	 stalk	 cells	 of	 growing	blood	vessels.	 It	 is	 furthermore	postulated	 that	 the	
sFlt1	 protein	 diffuses	 over	 long	 distances	 and	 aids	 in	 guiding	 sprouting	 angiogenesis.	We	
previously	 reported	 that	 vascular	 Flt1	 is	 dispensable	 for	 sprouting	 angiogenesis	 in	 the	
zebrafish	embryo	(Wild	et	al.	2017).	Instead,	we	found	that	neuronal	Flt1	controls	sprouting	
of	 intersegmental	 veins,	 a	 vascular	 domain	 that	 is	 actually	 expressing	 no	 or	 only	 limited	
levels	 of	 flt1.	We	 show	 that	 flt1	 is	 predominantly	 expressed	 in	 arteries,	 and	 we	 have	 no	
evidence	 for	 production	 being	 restricted	 to	 stalk	 cells	 only	 –	 we	 observe	 flt1	 along	 the	
arterial	sprouts	and	the	aorta.	We	thus	wondered	why	flt1	was	expressed	in	arteries	if	not	




in	 line	 TgTm(flt1_E3_HAHA)ka610,	 allowing	 visualization	 of	 Flt1	 protein	 by	
immunohistochemistry.	 We	 show	 that	 Flt1	 protein	 is	 localized	 at	 the	 endothelial	 cell	
membrane	or	in	very	close	proximity	to	the	arterial	vasculature.	In	addition,	at	the	single	cell	
level	we	find	abundant	Flt1	protein	inside	the	cell	and	the	cell	nucleus,	consistent	with	the	
nuclear	 localization	 signal	 (NLS)	 signal	 in	 the	 Flt1	 protein.	 As	 such	 it	 seems	 that	 Flt1	 is	
providing	 a	 “coating”	 around	 the	 arteries,	 presumably	 to	 protect	 against	 harmful	 Vegfaa	
dosages	coming	 from	the	developing	 skeletal	musculature	 surrounding	 the	 intersegmental	
vessels.	
	
To	 test	 for	 the	 biological	 relevance	 of	 arterial	 Flt1,	 we	 analysed	 a	 series	 of	 Flt1	 and	 Flt1	
ligand	 loss-	 and	 gain-of-function	 models.	 We	 show	 that	 loss	 of	 flt1	 augments	 arterial	
diameter	 and	 therefore	 decided	 to	 investigate	 this	 in	 more	 detail.	 Although	 loss	 of	 flt1	
predicts	Vegfaa	gain-of-function,	we	show	that	overexpression	of	vegfaa	–	both	constitutive	
and	 inducible	–	did	not	phenocopy	 loss	of	 flt1.	 Instead,	 in	 these	vegfaa	GOF	scenarios	we	
observed	 aberrant	 vascular	 remodelling	 and	 non-functional	 vasculatures	 as	 also	 observed	
previously	(Flamme	et	al.	1995).	With	such	GOF	approaches	Vegfaa	levels	can	rise	very	high,	
even	 up	 to	 the	 potentially	 toxic	 range.	 We	 thus	 argued	 that	 we	 needed	 more	 subtle	
elevations	 in	 local	 Vegfaa.	 Flt1	 selectively	 binds	 Plgf	 and	 Vegfb,	 and	 these	 ligands	 may	
compete	Vegfaa	away	from	Flt1	(Figure	32,Figure	33).	 In	addition,	both	Plgf	and	Vegfb	are	
specific	 to	 Flt1	 and	 do	 not	 bind	 to	 Kdrl,	 hence	 cannot	 activate	 Kdrl	 signalling	 (Rossi	 et	 al.	
2016).	 While	 Flt1:Kdr	 heterodimers	 may	 exist,	 their	 signalling	 efficiency	 has	 been	
controversially	 discussed	 (DiSalvo	 et	 al.	 1995;	 Cao	 et	 al.	 1996).	We	 furthermore	 have	 no	
evidence	 for	a	 functional	 role	of	mFlt1	 in	early	vascular	morphogenesis	 (Wild,	Klems	et	al.	
2017)	and	the	heterodimer	scenario	can	thus	be	disregarded	(Figure	33f).		
		
We	 cloned	 zebrafish	plgf	 and	 vegfb	 and	mapped	 their	 expression	 using	 a	 combination	 of	
WISH	 and	 transgenic	 reporters.	 We	 find	 that	 they	 are	 expressed	 in	 developing	 nervous	











outward	 remodelling,	 suggesting	 that	 outward	 remodelling	 is	 signalled	 through	 Kdrl	 and	
converges	onto	Akt.	
	




We	 show	 that	 in	 our	 setting,	 the	 remodelling	process	 does	not	 associate	with	 invasion	of	
macrophages	as	no	altered	macrophage	migration	was	observed	in	plgfcMC	embryos	(Figure	
18f).	 In	 flt1-/-	 mutants,	 macrophage	 distribution	 was	 also	 not	 associated	 with	 vascular	
development.	Thus,	in	contrast	with	other	studies	(Pipp	et	al.	2003)	but	in	line	with	Odorisio	
et	 al	 (2002),	 in	 our	 hands	 arteriogenesis/outward	 remodelling	 does	 not	 associate	 with	
macrophage	 accumulation.	 In	 conclusion:	 Plgf-mediated,	 Flt1-dependent	 outward	
remodelling	is	endothelial	cell-autonomous	and	not	influenced	by	macrophages	and	nerves.	
	
Interestingly,	 although	 arteries	 in	 flt1	mutants	 did	 not	 show	 ectopic	 branches	we	 do	 find	







process	 presented	 in	 this	 study	 will	 enable	 answering	 fundamental	 questions	 in	 vascular	








Flt1	 (sFlt1	 as	 depicted	 here,	 but	 also	mFlt1)	 limits	 Kdrl	 signalling	 by	 scavenging	Vegfaa.	 Vegfaa	 has	 a	 higher	
affinity	 to	 Flt1	 than	 to	 Kdrl,	 thereby	 Flt1	 is	 forming	 an	 arterial	 Vegfaa	 reservoir,	 the	 first	 level	 (1)	 of	 Vegfaa	
regulation.	 (b)	 Plgf	 competes	 with	 Vegfaa	 for	 Flt1	 binding,	 thereby	 eventually	 releases	 Vegfaa.	 This	 is	 the	
second	 level	 (2)	 of	 Vegfaa	 regulation.	 Nrp1	 binding,	 however,	might	 regulate	 Plgf	 bioavailability	 as	 possible	
third	level	of	Vegfaa	reservoir	regulation	(d).	(c)	In	turn,	Vegfaa	can	bind	to	Kdrl	and	induce	a	signalling	cascade	
involving	 Akt,	 but	 not	 ERK1/2,	 resulting	 in	 AOR.	 The	 contribution	 of	 Plcg	 remains	 to	 be	 established.	 (d’)	
Whether	 Plgf	 –	Nrp1	 signalling	 can	 contribute	 to	 outward	 remodelling	 remains	 to	 be	 determined.	 (e)	 Flow-
induced,	 ligand-independent	 Kdrl	 signalling	 can	 mediate	 arterial	 diameter	 in	 a	 mechanosensory	 complex	
(Baeyens	&	Schwartz	2016).	(f)	There	is	no	evidence	for	a	contribution	of	Flt1:Kdrl	heterodimers	to	arteriolar	
diameter	control.	 (g)	The	 implication	of	Plgf	–	mFlt1	signalling	 in	this	process	remains	to	be	established.	Pink	
arrows,	pathways	discovered	 in	 this	 study	 to	 regulate	arteriolar	diameter;	pink	dotted	arrows,	pathways	not	






Acute	 changes	 in	 blood	 flow	 are	 encountered	 with	 the	 production	 of	 vasodilative	
or	-constrictive	substances,	while	chronic	deviations	from	a	certain	shear	stress	range	induce	






viscosity	 is	 normally	 constant	 and	 vessel	 length	 does	 not	 vary	 much	 in	 a	 developed	
vasculature,	blood	vessel	resistance	and	flow	are	mainly	determined	by	the	vessel	radius.		
	
In	 all	 three	 arteriolar	 outward	 remodelling	 scenarios	 presented	 in	 this	 study,	 i.e.	 plgfcMC,	
vegfbcMC	and	flt1-/-,	the	vessel	diameter	normalized	at	around	3dpf.	Applying	the	shear	stress	
set	 point	 theory	 to	 the	 arterial	 outward	 and	 inward	 remodelling	 results	 in	 the	 model	
depicted	 in	 Figure	 34	 using	 the	 example	 of	plgfcMC	 embryos.	 The	 shear	 stress	 set	 point	 is	
assumed	 to	 be	 the	WT	 shear	 stress	 level	 (Figure	 34,	 dotted	 line).	 For	 simplicity,	 only	 R2	




rate	 at	 approximately	 1.5dpf,	 the	 shear	 stress	 is	 reduced	 by	 the	 factor	 8	 (Figure	 34a,e).	





Another	 factor	 contributing	 to	 the	 inward	 remodelling	 is	 probably	 that	 AV	 remodelling	
occurs	around	2dpf,	an	event	generating	circulating	and	stable	perfusion.	Hence	 it	 is	 likely	
that	 at	 this	 developmental	 stage	 hemodynamics	 starts	 to	 occupy	 a	 key	 role	 in	 vascular	
architecture	and	superimposes	the	R2	outward	remodelling	signalling.	How	shear	stress	set	
point	 sensing	 works	 is	 not	 completely	 understood	 so	 far.	 One	 model	 is	 the	 shear	 stress	
junctional	 mechanosensory	 complex	 in	 which	 VEGFR2	 or	 -3	 are	 associated	 with	 VE-
cadherin’s	transmembrane	domain;	mechanical	forces	on	platelet	endothelial	cell	adhesion	







adapt	accordingly	 to	prevent	underfilling	or	shock.	Murray	stated	 in	1926	that	 for	keeping	
the	energy	needed	for	appropriate	blood	supply	to	a	minimum,	the	cost	of	blood	production	
should	 equal	 the	 cost	 of	 pumping	 the	 blood	 through	 the	 vessels.	 With	 respect	 to	 the	
outward	 remodelling	presented	 in	 this	 study	 it	 is	 likely	 that	 although	 the	energy	 to	pump	



























To	 improve	 the	 disease	 outcome	 in	 patients	 with	 arteriolar	 occlusions	 it	 is	 important	 to	




but	 VEGF	mostly	 failed	 to	 reach	 the	 primary	 trial	 end	 points	 (Grundmann	 et	 al.	 2007).	 In	
other	 experimental	 settings,	 VEGF	 induced	 uncontrolled	 vascularization,	 suggesting	 that	
VEGF	 dosage	 is	 a	 major	 issue	 in	 therapeutic	 approaches.	 Here,	 we	 show	 that	 dosage	
limitations	might	be	overcome	by	taking	advantage	of	the	endogenous	arteriolar	Flt1-bound	
Vegfaa	 reservoir.	 By	 competitive	 binding	 with	 Plgf,	 Vegfaa	 can	 be	 released	 locally	 in	 the	
close	 vicinity	 of	 Kdrl,	 thereby	 doubling	 the	 arteriolar	 diameter.	 Vegfaa	 does	 not	 have	 to	
diffuse	far,	so	that	this	approach	does	probably	not	depend	on	the	ECM	composition.	
	
Importantly,	 one	would	 expect	 that	 increased	 Vegfaa	 levels	 cause	 increased	 permeability	
(Dor	 et	 al.	 2002)	 and	 thus	 vessel	 shrinkage,	 but	 the	 opposite	 happens	 in	 the	 Vegfaa	GOF	
scenarios	 shown	 in	 this	 study.	 In	 addition,	 no	 oedema	 formation	 could	 be	 observed.	
Therefore,	we	 suggest	 that	 Vegfaa	 release	 from	 the	 endogenous	 reservoir	 negotiates	 the	
obstacle	of	proper	dosage	for	stimulating	arteriogenesis.	
Plgf	 overexpression	 as	 Vegfaa	 replacement	 strategy	 was	 furthermore	 well	 tolerated	 with	





However,	 for	 efficient	 and	 persistent	 perfusion	 capacity	 it	 is	 essential	 that	 blood	 vessels	
undergo	maturation	by	pericytes	recruitment.	Thus,	the	stimulation	of	arteriogenesis	is	only	
beneficial	when	a	pro-angiogenic	stimulus	is	combined	with	a	maturation	factor	(Hinkel	et	al.	
2014).	 A	 highly	 interesting	 pathway	 is	 the	 Thymosinβ 4	 (Tβ 4)/	 Myocardin-related	
Discussion 
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transcription	 factor	 (MRTF)-4/	 serum	 response	 factor	 (SRF)	 axis,	 which	 induces	 both	
angiogenesis	via	CCN1	as	well	as	pericyte	recruitment	via	CCN2.	Tβ4	–MRTF-4	can	thereby	
improved	 collateral	 blood	 flow	 in	 different	 animal	 models	 of	 coronary	 and	 peripheral	
ischemia	(Hinkel	et	al.	2014).	As	the	zebrafish	ISVs	are	only	very	poorly	covered	by	pericytes	
during	 early	 embryonic	 stages	 (Wild,	 Klems	 et	 al.	 2017),	 the	 effect	 of	 arteriolar	 outward	
remodelling	 by	 Plgf	 will	 have	 to	 be	 further	 assessed	 in	 vessels	 that	 are	 covered	 with	





























































































































































(World	 Precision	 Instruments)	 in	 a	 needle	 puller	 (Sutter	 Instrument	 Co.).	 Embryos	 were	
injected	 into	 the	 cytoplasm	 at	 the	 one-cell	 stage	 by	 moving	 the	 needle	 with	 a	
micromanipulator	(World	Precision	Instruments)	 	and	by	applying	pressure	to	release	1-2nl	
with	the	FemtoJet	Microinjector	(Eppendorf).		
The	 injection	 solutions	 for	 transgenesis	 contained	 25ng/µl	 tol2	 transposase	 mRNA	 and	
25ng/µl	plasmid	DNA.	For	BAC	transgenesis	40	ng/µl	tol2	transposase	mRNA	and	200	ng/µl	
BAC	 DNA	 were	 co-injected.	 Generation	 of	 zebrafish	 plgf-/-	 mutants	 via	 CRISPR/Cas9	 was	
accomplished	by	injecting	25ng/µl	sgRNAplgf	Exon	3	with	300ng/µl	Cas9	mRNA.	
	




treated	 with	 0.125μM	 ki8751	 (Sigma).	 PI3K/AKT	 signalling	 was	 inhibited	 with	 1.25µM	
wortmannin	 (Sigma).	 Control	 embryos	 were	 treated	 with	 an	 equal	 volume	 of	 DMSO.	 For	





Tissue	 permeabilization	 of	 fixed	 embryos	 was	 achieved	 by	 a	 gradual	 transfer	 in	 100%	
Methanol	 (25,	 50,	 75%	 (v/v)	 in	1xPBT),	 followed	by	a	descending	Methanol	 series	back	 to	
PBT.	 Additional	 permeabilization	 was	 achieved	 using	 proteinase	 K	 at	 a	 concentration	 of	
10µg/ml	in	PBT	with	the	following	incubation	times:	embryos	at	24hpf	for	3min,	at	30hpf	for	
4min	 and	 at	 48hpf	 for	 8min.	 Subsequently,	 embryos	 were	 fixed	 in	 4%	 PFA	 for	 20min.	 In	
order	to	minimize	unspecific	background,	embryos	were	prehybridized	in	hybridization	mix	









Subsequently,	 non-specific	 antibody	 binding	 sites	were	 blocked	 by	 incubation	 in	 2%	 (w/v)	
Blocking	 Reagent	 in	 1xMAB-T.	 The	 alkaline	 phosphatase-conjugated	 antibody	 anti-
digoxigenin-AP,	 Fab	 fragments	 (Roche)	 was	 diluted	 1:4000,	 added	 to	 the	 mbryos	 and	
blocked	o/n	at	4°C.	Next,	the	embryos	were	washed	4	times	in	1xMAB-T	for	30min,	washed	
twice	 for	 15min	 in	NTMT	 (0.1M	Tris-HCl	pH	9.5;	 0.1M	NaCl;	 1%	Tween-20;	 50mM	MgCl2),	
followed	by	colour	development	in	the	dark	with	BM-Purple	(Roche),	a	colorimetric	alkaline	
phosphatase	substrate.	
Material and methods 
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6.2.2.2 Immunohistochemistry	
For	 permeabilizing	 fixed	 embryos	 a	 descending	 followed	by	 an	 ascending	methanol	 series	
was	performed	as	described	above	(6.2.2.1).	The	embryos’	heads	were	chopped	off	and	the	
bodies	were	 incubated	 for	2h	 in	a	blocking	buffer	 (1%	 (v/v)	Triton	X-100,	3%	 (w/v)	BSA	 in	
1xPBS).	The	primary	antibody	was	diluted	in	0.5%	(v/v)	Triton	X-100,	1%	(w/v)	BSA	in	1xPBS	
and	samples	were	incubated	o/n	at	4°C.	Embryos	were	washed	5	times	for	10min	with	PBT	




























In	 cases	where	no	 single	bands	could	be	obtained	 from	a	 single	PCR	 reaction,	 the	desired	






Hot	 Start	 II	 DNA	 polymerase	 in	 the	 Mastercycler	 GX2/GX2e	 (Eppendorf);	 for	 genotyping	
Material and methods 
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In	order	 to	maximize	 the	 specificity	 and	efficiency	of	 a	PCR,	 the	optimal	primer	annealing	





Nucleic	 acids	 were	 analysed	 with	 agarose	 gel	 electrophoresis.	 Samples	 were	 mixed	 with	
loading	buffer	(5x	loading	buffer:	0.5%	(w/v)	orange	G;	50%	(v/v)	glycerol;	25mM	EDTA;	pH	








Chemically	 competent	 E.	 coli	 strains	 were	 transformed	 with	 plasmids	 according	 to	 the	
manufacturer’s	descriptions,	plated	on	LB	agar	plates	(20g	LB	medium	ad	1l	H2O;	1.5%	(w/v)	
agar-agar)	supplemented	with	the	appropriate	antibiotic	and	incubated	o/n	at	37°C.	
DH5-α	 cells	 were	 used	 for	 re-transformations.	 Subcloning,	 blue/white	 screening	 and	
Gateway	clonings	were	performed	in	One	Shot	TOP10	Chemically	Competent	E.	coli	(Thermo	
Fisher	 Scientific).	 Cloning	 of	 plasmids	 encoding	 sgRNAs	 was	 accomplished	 in	 XL10-Gold	
Ultracompetent	Cells	(Agilent).	
	








If	 not	 stated	 otherwise,	 PCR	 reactions	 for	 subsequent	 cloning	 reactions	 were	 done	 with	
cDNA	 as	 template.	 After	 restriction	 enzyme	digest	 plasmids	were	 dephosphorylated	 using	
calf	 intestinal	alkaline	phosphatase	(NEB).	Ligation	was	done	with	T4	DNA	ligase	(NEB).	 ISH	
probes	were	cloned	into	the	pGEM-T	Easy	vector	(Promega)	according	to	the	manufacturer’s	























Flt1_XhoI_fw	 pCDNA3.1	 sFlt1_HAHA_Xba	 XhoI,	XbaI	





















Table 7| Gateway expression vector cloning	



































For	 the	 analysis	 of	 the	 endogenous	 expression	 of	 plgf,	 BAC	 transgenesis	 was	 performed	
according	to	Bussmann	&	Schulte-Merker	(2011),	involving	a	recombineering	procedure.	All	
transformations	were	carried	out	via	electroporation	with	standard	conditions	for	E.coli.	
Using	 the	 UCSC	 genome	 browser,	 two	 suitable	 BACs	 were	 identified	 (CH73-297E11	 and	
CH211-27O11,	 both	 with	 pTarBAC2.1	 backbone)	 and	 ordered	 from	 BacPAC	 Resources	
Center.	 Bacteria	 were	 tested	 for	 bearing	 the	 correct	 BAC	 with	 the	 primers	
plgf_HA1_control_fw	and	plgf_HA2_control_rev	in	a	colony	PCR.	Next,	the	bacteria	carrying	
the	 BAC	 were	 transformed	 with	 the	 pRedET	 vector	 containing	 genes	 of	 the	 homology-
directed	repair	machinery	that	was	essential	for	the	subsequent	recombineering	steps.	
In	order	to	enable	transgenic	insertion	of	the	BAC	via	the	tol2	transposon	system,	in	the	first	
recombineering	 step	 tol2	 sites	were	 inserted	 in	 the	BAC	backbone	by	 recombination	with	
the	PCR	product	derived	with	pTarBAC_HA1_iTol2_fw	and	pTarBAC_HA2_iTol2_rev	from	the	
plasmid	pCR8GW-itol2-amp	(kindly	provided	by	S.	Schulte-Merker).	Insertion	of	left	tol2	site	
was	 confirmed	by	 PCR	with	 pTarBAC_HA1_control_fw	 and	 amp_HA1_control_rev,	 of	 right	
tol2	site	with	amp_HA2_control_fw	and	pTarBAC_HA2_control_rev.	
Material and methods 
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In	the	second	recombineering	step,	mCitrine	was	inserted	behind	the	ATG	of	plgf.	








In	 vitro	 transcription	 (IVT)	 of	 Cas9-nls	 mRNA	was	 done	 with	 the	mMessage	MACHINE	 T7	
ULTRA	Transcription	Kit,	of	tol2	transposase	(pCS2FA,	Kwan	et	al.	2007)	with	the	mMessage	
MACHINE	SP6	ULTRA	Transcription	Kit,	and	sgRNAs	were	transcribed	with	the	MAXIscript	T7	
Transcription	 Kit	 according	 to	 the	 manufacturer’s	 instructions	 (all	 from	 Thermo	 Fisher	
Scientific).		
For	 ISH	RNA	probe	generation,	2µl	100mM	DTT	 (Sigma-Aldrich),	2µl	DIG	RNA	Labeling	Mix	
(Roche),	 1µl	 RNasin	 Ribonuclease	 Inibitor	 (Promega)	 and	 RNA	polymerase	with	 respective	
buffer	were	added	to	the	DNA	in	a	total	volume	of	20µl.	

























Using	 the	 online-tool	 CHOPCHOP,	 short	 guide	 RNAs	 (sgRNAs)	with	 the	 constraint	 NGG	 as	
PAM	sequence	were	identified.	Any	sequences	in	the	genome	with	up	to	three	mismatches	





NaCl;	1mM	EDTA);	 this	annealing	solution	was	heated	 for	5min	at	95°C	 in	a	heating	block,	
subsequently	let	cool	down	to	30°C	and	the	annealed	oligonucleotides	were	diluted	1:10	in	
H2O.	 For	 the	 o/n	 ligation	 at	 16°C	 with	 the	 T4	 DNA	 Ligase	 (NEB)	 a	 ratio	 of	 1:9	 of	 diluted	
annealed	oligos:digested	vector	was	used.		








by	 sequencing	 (Table	 9).	 These	 fish	 were	 again	 incrossed	 to	 obtain	 a	 homozygous	 plgf-/-	
(plgfka609/ka609)	mutant	line.	










pDestCG2_flt1enh_sflt1-HAHA	 by	 site-directed	 mutagenesis	 (SDM)	 with	 the	 primers	
SDM_Flt1delta7_fw	and	SDM_Flt1delta7_rev.	For	SDM	the	PCR	product	was	phosphorylated	
with	 T4	 polynucleotide	 kinase	 (NEB),	 followed	 by	 blunt	 end	 ligation	 with	 T4	 DNA	 ligase.	
Remaining	 template	plasmid	was	digested	with	DpnI.	The	 resulting	pDestCG2_flt1enh_sflt1-





HotSHOT	 (Hot	Sodium	Hydroxide	Tris)	method	 (Truett	et	al.	2000).	 In	brief,	 the	 tissue	was	
boiled	 in	 30-	 100µl	 alkaline	 solution	 (pH	 12)	 for	 20min	 at	 95°C,	 centrifuged,	 and	 1-5µl	
supernatant	were	used	as	PCR	template.	Mutants	with	insertion-deletion	mutations	(InDels)	
<10bp	were	sequenced,	InDels	≥10bp	were	analysed	on	a	3%	agarose	gel	(Table	9).	








Mutation	 Forward	Primer	 Reverse	Primer	 Analysis	
plgf-/-	 plgfka609	 -10bp	in	exon	3	 plgf_E3_gDNA_fw	 plgf_E3_gDNA_rev	 Gel	













































were	 passaged	 six	 times	 through	 a	 narrow-gauge	 needle	 (Sterican	 G27,	 B	 Braun)	 in	 lysis	
buffer	(50mM	HEPES	pH	7.4;	15mM	NaCl;	1mM	MgCl2;	10%	(v/v)	glycerol;	1%	(v/v)	Triton	X-
100),	 supplemented	with	 1x	 Protease	 Inhibitor	 Cocktail	 (Cell	 Signaling	 Technology)	 and	 1x	
phosphatase	 inhibitor	 PhosSTOP	 (Roche).	 Lysed	 embryos	 were	 centrifuged	 for	 10min	 at	
13.000rpm	at	4°C.	60µl	supernatant	was	cooked	at	95°C	for	5min	with	15µl	5x	Western	blot	












incubated	 for	30min	 in	5%	 (w/v)	nonfat	dry	milk	 in	TBS-T	 (50mM	Tris-HCl	pH	7.4;	150mM	
NaCl;	0.05%	(v/v)	Tween-20).	The	membrane	was	washed	three	times	 in	TBS-T,	and	the	1°	
antibody,	 diluted	 in	 TBS-T,	 was	 incubated	 o/n	 at	 4°C.	 Afterwards,	 the	 membrane	 was	
washed	again	with	TBS-T,	before	the	2°	antibody,	again	diluted	in	TBS-T,	was	added	for	2h	at	















H2O	 1.9	 1.6	 0.68	
30%	acryl-bisacrylamide	mix	 1.7	 2.0	 0.17	
1.5M	Tris	(pH	8.8)	 1.3	 1.3	 -	
5M	Tris	(pH	6.8)	 -	 -	 0.13	
10%	SCS	 0.05	 0.05	 0.01	
10%	ammonium	persulfate	 0.05	 0.05	 0.01	









































binding.	 Protein	 G	 Sepharose,	 Fast	 Flow	 beads	 (Sigma-Aldrich)	 were	 washed	 three	 times	
with	RIPA	buffer,	added	to	the	protein-antibody	solution	and	incubated	for	further	45min	at	
4°C	to	allow	antibody	binding	to	the	beads.	The	beads	were	washed	again	three	times	with	
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RIPA	 buffer	 before	 50µl	 H2O	 and	 10µl	 5x	Western	 blot	 loading	 buffer	were	 added	 to	 the	




For	 in	 vivo	 confocal	 imaging,	 embryos	were	 first	 anaesthetized	with	 0.7x	 Tricaine	 (Sigma-
Aldrich)	in	E3	and	subsequently	embedded	in	microscopy	dishes	(MatTek)	in	0.7x	(w/v)	low-
melting	 NuSieve	 GTG	 Agarose	 (Lonza)	 in	 E3	 medium.	 The	 hardened	 agarose	 was	 then	
covered	 with	 0.7x	 Tricaine	 in	 E3	 to	 keep	 the	 embryos	 anaesthetized	 during	 the	 imaging.	
Imaging	was	 done	with	 the	 Leica	 TCS	 SP8	 Confocal	 inverted	microscope	 using	 20x	 or	 40x	
objectives.	Time	lapse	images	were	performed	at	28.5°C.	
In	order	to	image	WISH	staining,	embryos	were	gradually	transferred	into	80%	glycerol	(v/v,	
















single	 TIF	 file;	 this	 TIF	 file	was	 converted	 to	 8-Bit	 and	 the	 pAKT/AKT	 and	 pERK/ERK	 ratios	
were	determined	for	every	sample	using	the	Gel	analysis	tool	of	Fiji.	




Statistical	 analysis	 was	 done	 with	 GraphPad	 Prism	 6.	 Results	 are	 presented	 as	 mean	 ±	
standard	 error	 of	 the	 mean	 (s.e.m.).	 In	 order	 to	 determine	 whether	 two	 data	 sets	 were	
significantly	 different	 from	 each	 other,	 the	 two-tailed	 Student’s	 t-test	 was	 used.	 The	

























































































































































































































































































































































































aISV	 	 	 arterial	intersegmental	vessel	
AV	 	 	 arteriovenous	
BAC	 	 	 bacterial	artificial	chromosome	
bp	 	 	 base	pair	
BSA	 	 	 bovine	serum	albumin	
CA	 	 	 costal	artery	
CaP	 	 	 caudal	primary	motoneuron	
Cas9	 CRISPR	associated	protein	9	
cDNA	 	 	 complementary	DNA	
cMC	 	 	 constitutive	muscle	cell-specific	GOF	
cNC	 	 	 constitutive	neuronal	cell	specific-GOF	
CNS	 	 	 central	nervous	system	
Co-IP	 	 	 Co-immunoprecipitation	
CRISPR	 Clustered	Regularly	Interspaced	Short	Palindromic	Repeats	
CtA	 	 	 central	artery	
CV	 	 	 cardinal	vein		
DA	 	 	 dorsal	aorta	
DIG	 	 	 digoxigenin	
DLAV	 	 	 dorsal	longitudinal	anastomotic	vessel	
Dll1-4	 	 	 delta-like	1-4	
DNA	 	 	 deoxyribonucleic	acid	
DNase	 	 	 deoxyribonuclease	
dNTP	 	 	 deoxynucleotide	triphosphate	
DOCK4/9	 	 dedicator	of	cytokinesis	4/9	
dpf	 	 	 days	post	fertilization	
DTT	 	 	 dithiothreitol	
EC	 	 	 endothelial	cell	
ECM	 	 	 extracellular	matrix	
EDTA	 	 	 ethylenediamine	tetraacetic	acid	
eGFP	 	 	 enhanced	green	fluorescent	protein	
eNOS	 	 	 endothelial	nitric	oxide	synthase	
ERK1/2	 	 extracellular-signal-regulated	kinase	1/2	
F-actin		 	 filamentous	actin	
FACS	 	 	 fluorescence-activated	cell	sorting	
FGF	 	 	 fibroblast	growth	factor	
Fli1a	 	 	 Fli1	proto-oncogene	
Flt1	 	 	 Fms-like	tyrosine	kinase1/VEGFR-1	
Flt4	 	 	 Fms-like	tyrosine	kinase	4/VEGFR-3	
GFP	 	 	 green	fluorescent	protein	
GOF	 	 	 gain	of	function	
Abbreviations 
 111 
HC	 	 	 hypochord	
HMS	 	 	 horizontal	myoseptum	
hpf	 	 	 hours	post	fertilization	
Ig	 	 	 immunoglobulin	
IHC	 	 	 immunohistochemistry	
iMC	 	 	 inducible	muscle	cell-specific	GOF	
ISV	 	 	 intersegmental	vessel	
IVT	 	 	 in	vitro	transcription	
kDa	 	 	 kilo	Dalton	
KDR	 	 	 kinase	insert	domain	receptor/VEGFR-2	
kdrl	 kinase	insert	domain	receptor-like	
LLN	 	 	 lateral	line	nerve	
LOF	 	 	 loss	of	function	
MAPK	 	 	 mitogen-activated	protein	kinase	
mFlt1	 	 	 membrane-bound	Flt1	
MMP	 	 	 matrix	metalloproteases	
MN	 	 	 motoneuron	
mRNA	 	 	 messenger	RNA	
NC	 	 	 notochord	
NICD	 	 	 Notch	intercellular	domain	
NICD	 	 	 Notch	intracellular	domain	
NLS	 	 	 nuclear	localization	signal	
NO	 	 	 nitric	oxide	
NRP1/2	 	 neuropilin-1/2	
NT	 	 	 neural	tube	
o/n	 	 	 over	night	
PAGE	 	 	 polyacrylamide	gel	electrophoresis	
PAV	 	 	 parachordal	vessel	
PBS	 	 	 phospate	buffered	saline	
PBS-T	 	 	 phospate	buffered	saline-Tween	20	
PCR	 	 	 polymerase	chain	reaction	
PCV	 	 	 posterior	cardinal	vein	
PFA	 	 	 paraformaldehyde	
PI3K	 	 	 phosphoinisitide-3	kinase	
PLCy	 	 	 Phospholipase	C	gamma	1	
PlGF	 	 	 placental	growth	factor	
PMN	 	 	 primary	motoneuron	
PTU	 	 	 1-phenyl-2-thiourea	
R2	 	 	 VEGFR-2	
RI	 	 	 remodelling	index	
RNA		 	 	 ribonucleic	acid	
RNase	 	 	 ribonuclease	
Abbreviations 
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rpm	 	 	 revolutions	per	minute	
RTK	 	 	 receptor	tyrosine	kinase	
s.e.m.	 	 	 standard	error	of	the	mean	
SDS		 	 	 sodium	dodecylsulfate	
sFlt1	 	 	 solube	Fms-like	tyrosine	kinase1/sVEGFR-1	
sgRNA	 	 	 short	guide	RNA	
SMC	 	 	 smooth	muscle	cell	
Taq	 	 	 Thermus	aquaticus	
TEMED	 	 N,	N,	N’,	N’-tetramethylethylendiamin	
Tg	 	 	 transgenic	
Tris	 	 	 tris(hydroxymethyl)-aminomethane	
VE-cadherin	 	 vascular	endothelial	cadherin	(cdh5)	
VEGF	 	 	 vascular	endothelial	growth	factor/	VEGF-A	
VEGFR		 	 vascular	endothelial	growth	factor	receptor	
vISV	 	 	 venous	intersegmental	vessel	
WISH	 	 	 whole-mount	in	situ	hybridization	
WT	 	 	 wild	type	
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